[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 600
1. Abdelouahed K, Laghmari M, Tachfouti S, Cherkaoui W, Khorassani M, M'Seffer FA, Mohcine Z: [T-cell acute lymphoblastic leukemia /orbital lymphoblastic lymphoma in children]. J Fr Ophtalmol; 2005 Feb;28(2):197-200
Genetic Alliance. consumer health - Orbital lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [T-cell acute lymphoblastic leukemia /orbital lymphoblastic lymphoma in children].
  • RESULTS: Incisional biopsy of the mass revealed after of histopathologic and immuno-histochemical evaluation a T-cell lymphoblastic lymphoma.
  • Systemic examination and bone marrow aspirate show a acute lymphoblastic leukemia.
  • A complete Remission was observed after 13 months of follow up.
  • CONCLUSION: Primary T-cell lymphoblastic lymphoma of the orbit is a rare entity in any age group, but it is very rare in children.
  • When tumors occurs in the orbit, it presents a challenging diagnosis problem, especially in pediatric patients.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell. Neoplasms, Multiple Primary. Orbital Neoplasms. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851954.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Ramos JC, Ruiz P Jr, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE Jr, Toomey NL, Andela V, Harhaj EW, Lossos IS, Harrington WJ Jr: IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood; 2007 Apr 1;109(7):3060-8
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy.
  • Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy.
  • AZT and IFN-alpha is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Sep 15;84(6):1942-9 [8080997.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3289-97 [7936653.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Genes Dev. 1995 Aug 15;9(16):1965-77 [7649478.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1283-94 [8657101.001]
  • [Cites] Intervirology. 1995;38(3-4):238-46 [8682622.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15989-94 [16236719.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] J Pathol. 2006 Apr;208(5):714-23 [16400625.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Blood. 1998 Jan 15;91(2):570-6 [9427711.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3557-61 [9808547.001]
  • [Cites] Genes Dev. 1999 Feb 15;13(4):382-7 [10049353.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):720-5 [10699955.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1281-92 [10770796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1613-22 [11080800.001]
  • [Cites] Cancer Lett. 2000 Nov 10;160(1):89-97 [11098089.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Oncologist. 2001;6(1):34-55 [11161227.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3640-50 [8670867.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S179-85 [8797721.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):743-51 [10354140.001]
  • [Cites] Exp Hematol. 1999 Jul;27(7):1168-75 [10390192.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2713-22 [10453013.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):101-17 [10462626.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):253-65 [15638862.001]
  • [Cites] J Cutan Pathol. 2005 Mar;32(3):227-34 [15701085.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1382-8 [15831528.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):63-9 [11472346.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6369-86 [11533227.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7098-103 [11704834.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1284-92 [11749693.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):111-20 [11846982.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1069-85 [12040438.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):685-94 [12079517.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3120-30 [12218129.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6751-65 [12360402.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2249-55 [12613509.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] Blood. 2003 May 1;101(9):3681-6 [12511414.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S21-6 [15202521.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S41-7 [15202524.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):247-53 [15249594.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] Haematol Blood Transfus. 1981;26:502-14 [6274766.001]
  • [Cites] J Exp Med. 1985 Dec 1;162(6):2169-74 [2866223.001]
  • [Cites] Blood. 1987 Nov;70(5):1407-11 [2889484.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • (PMID = 17138822.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA-10521; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / CA-082274; United States / NCI NIH HHS / CA / U01-CA-070058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA-Binding Proteins; 0 / HIVEN86A protein, human; 0 / Interferon Regulatory Factors; 0 / Interferon Type I; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / Recombinant Proteins; 0 / interferon regulatory factor-4; 4B9XT59T7S / Zidovudine
  • [Other-IDs] NLM/ PMC1852214
  •  go-up   go-down


3. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA: Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood; 2010 Jul 15;116(2):171-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
  • A pilot study was undertaken to assess the safety, activity, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acute myeloid leukemia in complete remission but with molecular evidence of WT1 transcript.
  • Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation, CD3+ T-cell interferon-gamma release, and WT1 peptide tetramer staining.
  • Of the 9 evaluable patients, 7 completed 6 vaccinations and WT1-specific T-cell responses were noted in 7 of 8 patients.
  • With a mean follow-up of 30 plus or minus 8 months after diagnosis, median disease-free survival has not been reached.
  • Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Leukemia, Myeloid, Acute / therapy. Oncogene Proteins / therapeutic use. Vaccination / methods. WT1 Proteins / therapeutic use
  • [MeSH-minor] Adult. Aged. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cytotoxicity, Immunologic. Disease-Free Survival. Female. HLA-A Antigens / genetics. HLA-A Antigens / immunology. HLA-A2 Antigen. Humans. Hypersensitivity, Delayed / immunology. Interferon-gamma / biosynthesis. Interferon-gamma / immunology. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Vaccines, Subunit / genetics. Vaccines, Subunit / immunology. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Immunization.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Dec 1;165(11):6047-55 [11086036.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1037-42 [14504104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Int J Cancer. 1998 Dec 9;78(6):740-9 [9833768.001]
  • [Cites] J Exp Med. 1998 Dec 21;188(12):2357-68 [9858522.001]
  • [Cites] Cancer Immunol Immunother. 2005 Aug;54(8):721-8 [16010587.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1318-23 [15920488.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1415-8 [15845894.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1324-32 [16219568.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):34-42 [16397021.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jul;55(7):850-60 [16220325.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):231-6 [16611662.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1293-8 [16533527.001]
  • [Cites] Leukemia. 2007 May;21(5):868-76 [17361230.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4547-55 [17671141.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1781-7 [10688838.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1613-6 [18256684.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5429-35 [18591546.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Nov;6(10):995-1002 [19176197.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • (PMID = 20400682.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00398138
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / PHS HHS / / P01 23766
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / Oncogene Proteins; 0 / Vaccines, Subunit; 0 / WT1 Proteins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2910606
  •  go-up   go-down


Advertisement
4. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K: Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood; 2010 Nov 18;116(20):4368-75
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
  • To identify factors to improve the outcomes of related and unrelated allogeneic stem cell transplantations (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia (Ph(-) ALL) in the first complete remission (CR1), we retrospectively analyzed 1139 Ph(-) ALL patients using the registry data, particularly the details of 641 patients transplanted in CR1.
  • Among patients transplanted in CR1, relapse rates were significantly higher in related allo-SCT compared with unrelated allo-SCT, and multivariate analysis demonstrated that less than 6 months from diagnosis to allo-SCT alone was associated with relapse.
  • On the other hand, nonrelapse mortality (NRM) was significantly higher in unrelated allo-SCT compared with related allo-SCT, and multivariate analysis demonstrated that 10 months or longer from diagnosis to allo-SCT, human leukocyte antigen mismatch, and abnormal karyotype were associated with NRM.
  • After a close consideration of these factors, the outcome of allo-SCT for adult Ph(-) ALL in CR1 could be improved.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Humans. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Rate. Tissue Donors. Transplantation, Homologous. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664060.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Braun C, Duffau P, Mahon FX, Rosier E, Leguay T, Etienne G, Michaud M: [Acute pancreatitis due to hypercalcemia revealing adult T-cell leukemia]. Rev Med Interne; 2007 Feb;28(2):116-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis due to hypercalcemia revealing adult T-cell leukemia].
  • INTRODUCTION: Hypercalcemia frequently occurs in the course of Adult T-cell leukemia/lymphoma (ATLL).
  • Biochemical tests showed severe hypercalcemia and the peripheral white blood cell count revealed an atypical lymphocytosis.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157965.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Xue SL, Wu DP, Sun AN, Tang XW: CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol; 2008 Feb;83(2):167-70
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
  • Patients with either relapsed or refractory T-cell acute lymphocytic leukemia (T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Achieving complete remission (CR) in these patients is difficult but crucial for the success of allo-HSCT.
  • After initial remission-induction therapy, two patients achieved CR, one showed a partial remission, and all relapsed soon.
  • The CAG regimen (cytosine arabinoside 10 mg/m(2) subcutaneously every 12 hr, day 1-14; aclarubicin 5-7 mg/m(2) intravenously daily, day 1-8; and concurrent use of G-CSF 200 microg/m(2)/day subcutaneously) was devised originally for the treatment of relapsed acute myelogenous leukemia.
  • The efficacy of CR-induction in T-ALL patients and the adverse effects of the CAG regimen need to be further studied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Aclarubicin / administration & dosage. Adolescent. Adult. Antigens, CD / genetics. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874449.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


7. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.
  • We developed a real-time bisulfite polymerase chain reaction assay and analyzed the methylation levels of p73, p15, and p57(KIP2) at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL(-) ALL.
  • In 123 (65%) patients, matched pretreatment samples were also studied and compared with remission ones: in 82 of those with initial aberrant methylation of at least one gene, 59 (72%) had no detectable methylation at remission and 23 (28%) had detectable residual methylation.
  • By multivariate analysis, the presence of residual p73 methylation was associated with a significant shorter duration of first complete remission (hazard ratio=2.68, P= .003) and overall survival (hazard ratio=2.69, P= .002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


8. Lamb LS Jr, Neuberg R, Welsh J, Best R, Stetler-Stevenson M, Sorrell A: T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry B Clin Cytom; 2005 May;65(1):37-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia.
  • This case represents an example of an unusual T-cell lymphoblastic leukemia/lymphoma syndrome associated with eosinophilia and myeloid malignancy in a young boy.
  • This case is one of only five reported "leukemic" variants of the disease and demonstrates the importance of considering this poor prognostic diagnosis in pediatric acute lymphoblastic leukemia.
  • This case also illustrates the importance of an interactive multidisciplinary approach to the laboratory evaluation of a leukemia patient.
  • [MeSH-major] Eosinophilia / complications. Leukemia, Myeloid, Acute / complications. Leukemia-Lymphoma, Adult T-Cell / complications. Lymphoma / complications
  • [MeSH-minor] Antigens, Surface / biosynthesis. Biopsy. Bone Marrow / pathology. Child. Cytogenetics. Flow Cytometry. Humans. Immunophenotyping. Lymph Nodes / pathology. Male. Prognosis. Remission Induction. Syndrome


9. Dearden CE: T-cell prolymphocytic leukemia. Med Oncol; 2006;23(1):17-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival.
  • It can readily be distinguished from other T-cell leukemias on the basis of the distinctive morphology, immunophenotype, and cytogenetics.
  • Consistent chromosomal translocations involving the T-cell receptor gene and one of two protooncogenes (TCL-1 and MTCP-1) are seen in the majority of cases and are likely to be involved in the pathogenesis of the disorder.
  • In previously untreated patients, complete remission rates of 100% have been reported.
  • However, relapse is inevitable and strategies using both autologous and allogeneic stem cell transplantation are currently being explored.
  • [MeSH-major] Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Immunophenotyping. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2411-22 [8843194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2331-4 [12613520.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Science. 1985 Mar 1;227(4690):1044-7 [3919442.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1923-7 [8634440.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5452-6 [9407948.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):336-41 [11241786.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):921-7 [8703826.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 16645226.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


10. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • PATIENTS AND METHOD: Between 1993 and 2003, 81 adult patients from 22 Spanish hospitals were included in two PETHEMA protocols: ALL-96 for standard-risk patients, and ALL-93 for high- risk patients.
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


11. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • Initial treatment often includes zidovudine/interferon (IFN)-based therapy, although disease remission is typically not complete or durable.
  • He tolerated 8 cycles of denileukin diftitox therapy well and experienced a sustained complete hematologic and CNS remission.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Arsenicals / administration & dosage. Drug Resistance, Neoplasm / drug effects. Humans. Interferons / administration & dosage. Male. Middle Aged. Oxides / administration & dosage. Recombinant Fusion Proteins / administration & dosage. Recurrence. Remission Induction. Transplantation, Homologous. Zidovudine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


12. Sakai C, Murotani N: [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone]. Gan To Kagaku Ryoho; 2010 Feb;37(2):347-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult T-cell leukemia/lymphoma in a patient on hemodialysis-resistance to CHOP, but unexpected effect and remission achieved by sobuzoxane alone].
  • The pathological diagnosis was peripheral T-cell lymphoma, CD4(+).
  • He was clinically diagnosed as having an adult T-cell leukemia/lymphoma, lymphoma type, and clinical stage II.
  • At the time of reporting, May 2009, the patient was well without recurrence of ATLL, and the remission has lasted 26 months or more.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Piperazines / therapeutic use. Renal Dialysis. Renal Insufficiency / complications
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154500.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperazines; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; R1308VH37P / sobuzoxane; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Okamura J, Uike N, Utsunomiya A, Tanosaki R: Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol; 2007 Aug;86(2):118-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) develops in elderly individuals who have been infected with human T-cell leukemia virus type 1 (HTLV-1), and the prognosis for patients with ATLL has been extremely poor.
  • Retrospective studies of allogeneic stem cell transplantation (alloSCT) for selected populations of patients have achieved several encouraging results; however, the reported incidence of transplantation-related mortality (TRM) have been high, even though more than 80% of patients received stem cells from related donors and the patients were relatively young for ATLL.
  • The results of alloSCT are promising, and 30% to 40% of patients who achieve remission and have suitable donors can now become long-term survivors with either conventional alloSCT or RIST.
  • It is clear that a graft-versus-ATLL effect is present after alloSCT, regardless of the conditioning regimen or the stem cell source.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Middle Aged. Prospective Studies. Remission Induction. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Viral Load

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Hematol. 2002 Jul;76(1):91-3 [12138903.001]
  • [Cites] Bone Marrow Transplant. 1987 Dec;2(4):441-4 [3332192.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9 [17222757.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):357-61 [16298831.001]
  • [Cites] Cancer Sci. 2005 May;96(5):249-55 [15904464.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):304-9 [12542491.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):596-601 [15245597.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] N Engl J Med. 2006 Apr 20;354(16):1758-9 [16625020.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):87-9 [10037056.001]
  • [Cites] Leukemia. 2005 May;19(5):829-34 [15744352.001]
  • (PMID = 17875524.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


14. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


15. Alduaij A, Butera JN, Treaba D, Castillo J: Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):480-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
  • BACKGROUND: Acute T-cell leukemia/lymphoma (ATLL) is a post thymic (peripheral) T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • CASE REPORTS: We present 2 patients diagnosed with ATLL who were treated with hyper-CVAD chemotherapy and have achieved a durable complete remission.
  • One of the patients has gone on to receive an allogeneic bone marrow transplantation and has been in complete remission for over 18 months.
  • The other has been in a continuous remission for approximately 12 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Remission Induction. Transplantation, Homologous. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156467.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


16. Gu YY, Chen JH, Ouyang J: [Activation ability of CpG ODNs 2216 on PBMNCs from leukemia patients in remission and killing effect of activated PBMNCs on K562 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug;17(4):874-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Activation ability of CpG ODNs 2216 on PBMNCs from leukemia patients in remission and killing effect of activated PBMNCs on K562 cells].
  • The aim of this study was to investigate the activation ability of CpG oligodeoxynucleotide (CpG ODN) 2216 on the peripheral blood mononuclear cells (PBMNCs) from leukemia patients in remission and the killing effect of activated PBMNCs on K562 cells.
  • PBMNCs obtained from leukemia patients in remission were incubated with CpG ODN 2216.
  • The concentrations of cytokines (IFN-gamma, interleukin-12, interleukin-4, interleukin-10) in culture supernatant of PBMNCs from leukemia patients in remission were analyzed by using ELISA kits.
  • It is concluded that CpG ODNs 2216 can induce strong Th1-like immune activation, with the secretion of type-I cytokine and activation of strong CD8(+) T-cell responses.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19698220.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CpG ODN 2216; 0 / Oligodeoxyribonucleotides; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


17. Al Khabori M, Samiee S, Fung S, Xu W, Brandwein J, Patterson B, Brien W, Chang H: Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy. Acta Haematol; 2008;120(1):5-10
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult precursor T-lymphoblastic leukemia/lymphoma with myeloid-associated antigen expression is associated with a lower complete remission rate following induction chemotherapy.
  • Prognostic studies of T-cell lymphoblastic leukemia/lymphoma (T-ALL) have been performed in small patient cohorts with conflicting results.
  • We systematically reviewed 67 adult T-ALL patients diagnosed and treated at our institute to identify clinical and pathologic prognostic factors.
  • Fifty-six of 64 patients (88%) achieved complete remission (CR).
  • Our study indicates that expression of myeloid-associated antigens is associated with a lower CR rate in adult T-ALL and may be considered in risk stratification for induction chemotherapy.
  • [MeSH-major] Antigens, Differentiation, Myelomonocytic / metabolism. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, CD34 / metabolism. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neprilysin / metabolism. Prognosis. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Survival Rate

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • [CommentIn] Expert Rev Hematol. 2009 Feb;2(1):27-9 [21082991.001]
  • (PMID = 18635939.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


18. Parovichnikova EN, Gal'tseva IV, Vorob'ev IA, Savchenko VG: [Characteristics of T-cell immunity in patients with acute leukemia]. Ter Arkh; 2006;78(7):18-25
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of T-cell immunity in patients with acute leukemia].
  • AIM: To study a cytokine profile of cytotoxic T-cells and T-helpers at diagnosis of acute myeloid and lymphoblastic leukemia (AML and ALL) and at different stages of its treatment.
  • MATERIAL AND METHODS: T-cell population of peripheral blood lymphocytes was studied in 19 AML patients at diagnosis, 13 AML patients in remission, 5 AML patients in developing recurrence and 5 ALL patients at diagnosis.
  • The percentage of CD3+CD8- cells (T-helpers) producing IF-g was similar in the patients at diagnosis and in complete remission being higher than in healthy donors.
  • CONCLUSION: The results obtained evidence for different polarization of T-cell immunity in AML and ALL patients at the time of diagnosis, remission and recurrence: in the onset of AML there was an increase in the production of Th1--proinflammatory cytokines, in ALL--in percent of Th-2 cytokines.
  • [MeSH-major] Leukemia / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antigens, CD / biosynthesis. Antigens, CD / immunology. Cytokines / biosynthesis. Cytokines / immunology. Female. Flow Cytometry. Humans. Immunity, Cellular. Male. Middle Aged. Th1 Cells / immunology. Th1 Cells / metabolism. Th2 Cells / immunology. Th2 Cells / metabolism

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944746.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines
  •  go-up   go-down


19. Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M: Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma. Am J Clin Pathol; 2010 Apr;133(4):592-601
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
  • Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL).
  • We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences.
  • Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes.
  • In 2 patients, there was complete remission; 4 patients had disease refractory to therapy, and 3 died; 11 others had persistent disease with variable numbers of ATLL cells in the peripheral blood.
  • [MeSH-major] Flow Cytometry. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / genetics. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231613.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


20. Jabbour EJ, Faderl S, Kantarjian HM: Adult acute lymphoblastic leukemia. Mayo Clin Proc; 2005 Nov;80(11):1517-27
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia.
  • Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL).
  • Adaptation of successful treatment strategies in children with ALL has resulted in similar complete remission rates in adults.
  • Prognosis has Improved especially in mature B-cell ALL and T-cell lineage ALL.
  • Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Humans. Prognosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295033.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


21. Yamasaki R, Miyazaki Y, Moriuchi Y, Tsutsumi C, Fukushima T, Yoshida S, Taguchi J, Inoue Y, Matsuo E, Imaizumi Y, Imanishi D, Fujimoto T, Tsushima H, Honda S, Hata T, Tsukasaki K, Tomonaga M: Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia; 2007 Jun;21(6):1212-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can provide long-term remission for patients with adult T-cell leukemia/lymphoma (ATLL) caused by human retrovirus, human T-lymphocyte virus (HTLV-1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Humans. Polymerase Chain Reaction. Remission Induction. Tissue Donors. Transplantation, Homologous. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410191.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Kannagi M: Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol; 2007 Aug;86(2):113-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.
  • Host T-cell responses to human T-cell leukemia virus type I (HTLV-I) control the expansion of HTLV-I-infected cells and are determinants of the equilibrium proviral load in vivo.
  • Insufficient T-cell responses are regarded as an immunologic risk factor for adult T-cell leukemia (ATL) because they allow increased proviral loads, which represent an epidemiologic risk factor for ATL.
  • Tax-specific CTL responses are strongly activated after hematopoietic stem cell transplantation in some ATL patients in long-term remission, indicating that HTLV-I Tax is expressed in vivo rather than being silent, and that the donor-derived T-cell system can recognize it.
  • [MeSH-major] Human T-lymphotropic virus 1 / immunology. Immunity. Leukemia-Lymphoma, Adult T-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Aug 15;80(4):1012-6 [1498321.001]
  • [Cites] J Infect. 1986 May;12(3):205-12 [3014007.001]
  • [Cites] J Virol. 2005 Aug;79(15):10088-92 [16014972.001]
  • [Cites] J Virol. 1998 Sep;72(9):7289-93 [9696824.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1775-83 [11734593.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):81-4 [15198736.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int J Cancer. 1987 Dec 15;40(6):755-7 [2891625.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Curr Opin Immunol. 2000 Aug;12(4):397-402 [10899027.001]
  • [Cites] Leukemia. 2004 Jan;18(1):126-32 [14574331.001]
  • [Cites] J Virol. 2006 Aug;80(15):7375-81 [16840318.001]
  • [Cites] J Virol. 1990 Mar;64(3):1278-82 [2304144.001]
  • [Cites] Immunity. 2000 Nov;13(5):657-64 [11114378.001]
  • [Cites] J Virol. 1992 May;66(5):2928-33 [1373197.001]
  • [Cites] Gan. 1982 Apr;73(2):341-4 [6981536.001]
  • [Cites] Blood. 2005 May 15;105(10):4143-5 [15665110.001]
  • [Cites] J Virol. 2003 Mar;77(5):2956-63 [12584320.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Int J Cancer. 1998 Jul 17;77(2):188-92 [9650550.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] J Immunol. 1984 Aug;133(2):1037-41 [6203964.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):391-9 [14729650.001]
  • [Cites] J Virol. 1999 Aug;73(8):6436-43 [10400737.001]
  • [Cites] Annu Rev Immunol. 1997;15:15-37 [9143680.001]
  • [Cites] Int J Cancer. 1991 Feb 20;47(4):491-5 [1995478.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):257-67 [15551352.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Virology. 1992 Jun;188(2):628-36 [1374983.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1567-73 [8496677.001]
  • [Cites] J Virol. 2000 Jan;74(1):428-35 [10590132.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3065-73 [8874205.001]
  • (PMID = 17875523.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 39
  •  go-up   go-down


23. Yamada T, Mishima K, Ota A, Moritani N, Matsumura T, Katase N, Yamamoto T: A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jun;109(6):e51-5
MedlinePlus Health Information. consumer health - Tooth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ATLL (adult T-cell leukemia/lymphoma) mimicking odontogenic infection.
  • A case of adult T-cell leukemia/lymphoma (ATLL) in which cheek swelling was the initial symptom is presented.
  • However, remission was not achieved.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Maxilla / pathology. Periapical Abscess / pathology. Soft Tissue Infections / pathology. Tooth Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20451832.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C: Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood; 2006 Aug 1;108(3):1021-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
  • Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of poor prognosis.
  • Here, we report that enduring AZT treatment of T-cell leukemia virus I-infected cells, in vitro and in vivo in ATL patients, results in inhibition of telomerase activity, progressive telomere shortening, and increased p14(ARF) expression.
  • In turn, this elicits stabilization and reactivation of the tumor suppressor p53-dependent transcription, increased expression of the cyclin-dependent kinase inhibitor p21(Waf1), and accumulation of p27(kip1), thereby inducing cellular senescence and tumor cell death.
  • While ATL patients carrying a wild-type p53 enter remission following treatment with AZT, those with a mutated p53 did not respond, and patients' disease relapse was associated with the selection of a tumor clone carrying mutated inactive p53.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Leuk Res. 1999 Mar;23(3):311-6 [10071087.001]
  • [Cites] Br J Dermatol. 1989 May;120(5):709-13 [2527052.001]
  • [Cites] Blood. 1992 Jan 15;79(2):477-80 [1730092.001]
  • [Cites] EMBO J. 1992 May;11(5):1921-9 [1582420.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5075-8 [10537276.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5514-20 [10554028.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):273-85 [10594030.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1043-8 [10706122.001]
  • [Cites] Leukemia. 2000 Apr;14(4):716-21 [10764160.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 May 20;16(8):709-13 [10826477.001]
  • [Cites] Int J Hematol. 1999 Apr;69(3):203-5 [10222661.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2441-50 [10229195.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2388-99 [10500096.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1164-70 [10502820.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):393-9 [15621829.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Virol. 2005 Jul;79(14):9346-50 [15994832.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3939-44 [10845931.001]
  • [Cites] Blood. 2000 Jul 1;96(1):275-81 [10891462.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1677-81 [11080809.001]
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):200-5 [11036071.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2137-44 [11264182.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):445-52 [11331871.001]
  • [Cites] Leuk Lymphoma. 2001 Jan;40(3-4):287-94 [11426550.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7029-40 [11704827.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3762-9 [11739184.001]
  • [Cites] Methods Cell Sci. 2001;23(1-3):17-22 [11741140.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):249-51 [11860671.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):452-3 [12167696.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33766-75 [12097320.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4129-38 [12393612.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8776-85 [12483531.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5113-21 [12860999.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1490-7 [15155458.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2523-31 [15226182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Cell. 1992 Jun 26;69(7):1237-45 [1535557.001]
  • [Cites] Oncogene. 1993 Nov;8(11):3029-36 [8414503.001]
  • [Cites] Blood. 1995 May 15;85(10):2699-704 [7742529.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Mol Cell Biol. 1996 Jan;16(1):53-65 [8524329.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2341-5 [9192804.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1271-4 [9359704.001]
  • [Cites] J Virol. 1998 Feb;72(2):1165-70 [9445014.001]
  • [Cites] Leuk Lymphoma. 1998 Mar;29(1-2):27-35 [9638973.001]
  • [Cites] J Virol. 1998 Aug;72(8):6348-55 [9658074.001]
  • [Cites] Nat Biotechnol. 1998 Aug;16(8):743-7 [9702772.001]
  • [Cites] J Virol. 1998 Nov;72(11):8852-60 [9765430.001]
  • [Cites] EMBO J. 1986 Nov;5(11):2883-8 [3024966.001]
  • (PMID = 16569765.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106258; United States / NCI NIH HHS / CA / R01CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 4B9XT59T7S / Zidovudine; EC 2.7.7.49 / Telomerase
  • [Other-IDs] NLM/ PMC1895862
  •  go-up   go-down


25. Ferrara F, Finizio O, Izzo T, Riccardi C, Criscuolo C, Carbone A, Borlenghi E, Rossi G: Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission. Anticancer Res; 2010 Sep;30(9):3845-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission.
  • Relapse still occurs in approximately 20-30% of patients with acute promyelocytic leukemia (APL) and, after achievement of second complete remission (CR), the optimal strategy is still controversial.
  • We describe therapeutic results from a series of 13 patients autografted in second molecular remission (MR) by a molecular negative apheresis product.
  • In all patients, the disease was confirmed at the molecular level and all had received the GIMEMA/AIDA protocol, achieving molecular remission at the end of consolidation.
  • In all cases, molecular evaluation of the apheresis product was negative for the promyelocytic leukemia/retinoic acid receptor alpha gene.
  • No maintenance or consolidation therapy after autologous stem cell transplantation (ASCT) was given to any patient.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Promyelocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944181.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


26. Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U: Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplant; 2005 Dec;36(12):1083-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
  • A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving autologous blood stem cell transplantation (ABSCT) were investigated in order to determine factors affecting outcome.
  • All but two patients had a normal karyotype and received the same high-dose chemotherapy followed by G-CSF-mobilized peripheral blood stem cells after the second (n=5) or third (n=17) course of induction and post-remission chemotherapy, respectively.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cells / cytology. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Antineoplastic Agents / pharmacology. Blood Platelets. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / metabolism. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Humans. Karyotyping. Leukapheresis. Male. Megakaryocytes / cytology. Middle Aged. Mutation. Remission Induction. Stem Cells / cytology. Time Factors. Transplantation, Autologous / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247435.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


27. Michallet AS, Chelghoum Y, Thiebaut A, Le QH, Prebet T, Tavernier E, Antal D, Nicolini F, Troncy J, Elhamri M, Michallet M, Thomas X: Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience. Hematology; 2006 Jun;11(3):157-64
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: the Edouard Herriot Hospital experience.
  • We retrospectively assess the long-term outcome and determined prognostic factors correlated with outcomes in adults with acute myeloid leukemia (AML) undergoing autologous hematopoietic stem cell transplantation (HSCT) in our institution over a 19-year period.
  • A total of 78 adults who received autologous HSCT for AML in first complete remission (CR) and of 21 adults in further CR were included in the study.
  • We confirmed that long-term EFS can be achieved after autologous HSCT in adult patients with AML.
  • [MeSH-major] Bone Marrow Transplantation / statistics & numerical data. Leukemia, Myeloid / surgery. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Salvage Therapy
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Transplantation Conditioning / adverse effects. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325955.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia; 2006 Feb;20(2):336-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.
  • To evaluate the results of autologous stem cell transplantation (ASCT) in a large population of adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR), we performed an individual data-based overview of the last three trials from the LALA group.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Recurrence. Remission Induction. Risk Factors. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357838.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Torelli GF, Guarini A, Maggio R, Alfieri C, Vitale A, Foà R: Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission. Haematologica; 2005 Jun;90(6):785-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
  • The anti-leukemic activity of NK cells against acute myeloid leukemia (AML) blasts has been described, but very few data are available for acute lymphoid leukemia (ALL).
  • The present study was designed to investigate whether: (i) NK effectors could be expanded from adult and pediatric ALL patients in complete remission;.
  • (v) any differences in cytotoxic activity could be found between expanded effectors from adult and pediatric patients.
  • DESIGN AND METHODS: We co-cultured patients' peripheral blood mononuclear cells (PBMC) with the feeder cell line RPMI 8866 and analyzed the NK cells' expansion capacity by cell count and cytofluorimetric analyses.
  • 51Cr release assays, before and after stimulation with activating cytokines, were performed to analyze the cytotoxic potential of effector cells against tumor cell lines and autologous blast cells.
  • Patients' expanded cells showed cytotoxic activity against target cell lines comparable to that of normal donors.
  • No differences in expansion and cytotoxic activity were found between pediatric and adult patients.
  • INTERPRETATION AND CONCLUSIONS: These findings document for the first time the possibility of expanding ex vivo cytotoxic effectors with autologous killing capacity from ALL patients in remission, and suggest a new potential immunotherapeutic strategy for the management of early disease recurrence or of residual disease.
  • [MeSH-major] Immunotherapy / methods. Killer Cells, Natural / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Child. Coculture Techniques. Cytokines / metabolism. Flow Cytometry. Humans. Interleukin-15 / metabolism. Interleukin-2 / metabolism. Receptors, IgG / metabolism. Remission Induction. Signal Transduction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951291.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-15; 0 / Interleukin-2; 0 / Receptors, IgG
  •  go-up   go-down


30. Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, Tanosaki R, Utsunomiya A, Uike N, Yoshida S, Okamura J, Tomonaga M: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia; 2005 May;19(5):829-34
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy.
  • Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL.
  • All evaluable cases entered complete remission (CR) after allo-HSCT and the median survival time was 9.6 months for all patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Analysis of Variance. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / therapy. Humans. Japan / epidemiology. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744352.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


31. Wlodarski MW, O'Keefe C, Howe EC, Risitano AM, Rodriguez A, Warshawsky I, Loughran TP Jr, Maciejewski JP: Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood; 2005 Oct 15;106(8):2769-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia.
  • T-cell large granular lymphocyte (T-LGL) leukemia is a clonal lymphoproliferation of cytotoxic T cells (CTLs) associated with cytopenias.
  • The antigen-specific portion of the T-cell receptor (TCR), the variable beta (VB)-chain complementarity-determining region 3 (CDR3), can serve as a molecular signature (clonotype) of a T-cell clone.
  • Our method also allowed for the measurement of clonal frequencies; a decrease in or loss of the pathogenic clonotype and restoration of the TCR repertoire was found after hematologic remission.
  • The data suggest a nonrandom clonal selection in T-LGL, possibly driven by a common antigen.
  • [MeSH-major] Leukemia, Lymphoid / immunology. Leukemia, Lymphoid / pathology. Receptors, Antigen, T-Cell / immunology. T-Lymphocytes, Cytotoxic / immunology. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clone Cells / immunology. Clone Cells / pathology. Disease Progression. Gene Expression Regulation. Humans. Middle Aged


32. Maggio R, Peragine N, Calabrese E, De Propris MS, Intoppa S, Della Starza I, Ariola C, Vitale A, Foà R, Guarini A: Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma; 2007 Feb;48(2):302-10
MedlinePlus Health Information. consumer health - Immunization.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission.
  • The capacity to generate effective dendritic cells (DC) from adult acute lymphoblastic leukemia (ALL) patients in complete remission (CR) and off-therapy was investigated.
  • DC loaded with leukemia-derived apoptotic bodies increased their ability to stimulate both allogeneic and autologous lymphocytes, and to generate specific anti-leukemic CD3 + cells.
  • These findings offer a rationale for the design of DC-based vaccine programs for adult ALL patients in CR with the aim of controlling/eradicating the disease.
  • [MeSH-major] Apoptosis. Dendritic Cells / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Vaccination
  • [MeSH-minor] Adult. Aged. Cancer Vaccines / therapeutic use. Cell Proliferation. Female. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunophenotyping. Interferon-gamma / metabolism. Interleukin-12 / metabolism. Interleukin-4 / pharmacology. Killer Cells, Natural / immunology. Male. Middle Aged. Phagocytosis. Remission Induction. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. T-Lymphocytes, Cytotoxic / immunology. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / pharmacology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Feb;48(2):217-8 [17325876.001]
  • (PMID = 17325890.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


33. Yoshimi A, Taoka K, Nakasone H, Iijima K, Kida M, Iki S, Urabe A, Usuki K: [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]. Rinsho Ketsueki; 2006 Dec;47(12):1533-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia].
  • We report a case of an adult patient with acute lymphoblastic leukemia (ALL) who developed SSST during the remission induction therapy.
  • He received a 1-AdVP regimen as remission induction therapy and intrathecal administration of methotrexate and cytarabine.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / administration & dosage. Asparaginase / adverse effects. Central Nervous System Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sagittal Sinus Thrombosis / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Facial Paralysis / etiology. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Remission Induction. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233472.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


34. Marks DI, Pérez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ: Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood; 2008 Jul 15;112(2):426-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
  • We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004.
  • A total of 50% had a white blood cell count (WBC) more than 30 x 10(9)/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia.
  • In multivariate analyses, TRM was significantly higher with HLA-mismatched donors and T-cell depletion.
  • Factors associated with poorer survival included WBC more than 100 x 10(9)/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2005 Mar;35(6):549-56 [15756282.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Dec;14(4):793-805 [11924922.001]
  • [Cites] Haematologica. 2003 May;88(5):555-60 [12745275.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1619-28 [7632972.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):153-8 [9489632.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2236-46 [10498594.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):683-9 [16113673.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53 [16545728.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5695-702 [17116940.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 Jul 1;110(1):409-17 [17374741.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):212 [18606879.001]
  • [CommentIn] Blood. 2008 Jul 15;112(2):447-8; author reply 448-9 [18606892.001]
  • (PMID = 18398065.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2442751
  •  go-up   go-down


35. Ge W, You SG, Wang YF, Li CH, Liu XF, He XP, Ma S, Qiu L: [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):461-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
  • OBJECTIVE: To assess the feasibility and efficiency of eliciting leukemia-specific T cell responses in acute myeloid leukemia patients in complete remission (AML-CR) in vitro by dendritic cells (DC) pulsed with the leukemia cells total RNA.
  • METHODS: The immature DCs were generated from the adherent bone marrow mononuclear cell in vitro in the presence of combined cytokines (GM-CSF 100 ng/ml, IL-4 500 U/ml), and pulsed with total RNA isolated from autologous leukemic cells by cationic lipid 1,2-dioleoyloxy-3-trimethyl ammonium propane (DOTAP) at day 5 of culture.
  • The proliferative capacity of T cell activated by mRNA-DC was determined by MTT assay.
  • An expansion of mRNA reacted T cell secreting IFN-gamma could be observed on ELISPOT assay.
  • CONCLUSION: Immunization with DC-leukemia cell RNA vaccines may be a simple, rapid and potent approach to elicitation of T cell-mediated anti-leukemia immunity.
  • [MeSH-major] Dendritic Cells / immunology. Leukemia, Myeloid, Acute / immunology. RNA / pharmacology. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Adult. Cell Communication. Cells, Cultured. Coculture Techniques. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383235.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 63231-63-0 / RNA
  •  go-up   go-down


36. Nishiwaki S, Terakura S, Yasuda T, Imahashi N, Sao H, Iida H, Kamiya Y, Niimi K, Morishita Y, Kohno A, Yokozawa T, Ohashi H, Sawa M, Kodera Y, Miyamura K: Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. Int J Hematol; 2010 Apr;91(3):419-25
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission.
  • The indication of allogeneic stem cell transplantation (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia [Ph(-) ALL] from unrelated donors is not established.
  • To assess its potency of unrelated patients in first complete-remission (CR1) transplanted from unrelated donors and the potential prognostic factors affecting the probability of survival, we retrospectively analyzed a total of 41 adult Ph(-) ALL patients in CR1 who underwent unrelated bone marrow transplantation at 6 transplantation centers of the Nagoya Blood and Marrow Transplantation Group between 1993 and 2006.
  • Leukemia-free survival (LFS) at 3 and 6 years from allo-SCT was 60.3 and 47.7%, respectively.
  • Our study suggested that unrelated allo-SCT could improve LFS of patients with a potential graft-versus-leukemia effect.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Histocompatibility / immunology. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Graft vs Host Disease / immunology. Graft vs Host Disease / mortality. Humans. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Retrospective Studies. Tissue Donors. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):115-21 [15908969.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Bone Marrow Transplant. 1989 Jul;4(4):445-8 [2673466.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):669-76 [9531332.001]
  • [Cites] Semin Oncol. 2000 Oct;27(5):540-59 [11049022.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):381-7 [17563735.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Haematologica. 1999 Oct;84(10):937-45 [10509043.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1408-16 [15486071.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Int J Hematol. 1998 Dec;68(4):421-9 [9885441.001]
  • [Cites] Chest. 2005 Jul;128(1):153-61 [16002929.001]
  • [Cites] Haematologica. 2004 Feb;89(2):145-53 [15003889.001]
  • [Cites] Bone Marrow Transplant. 2001 Sep;28(5):425-34 [11593314.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):45-50 [16258531.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Apr;10(2):293-320 [8707757.001]
  • [Cites] N Engl J Med. 1999 Jul 1;341(1):14-21 [10387937.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Int J Hematol. 1998 Oct;68(3):279-89 [9846012.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Respiration. 2004 Jul-Aug;71(4):301-26 [15316202.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4200-6 [12010826.001]
  • [Cites] Blood. 1981 Feb;57(2):267-76 [7004534.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1375-82 [18988865.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Transplant Proc. 1989 Jun;21(3 Suppl 1):51-62 [2662536.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):289-96 [16400341.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Int J Hematol. 2007 Feb;85(2):163-9 [17321996.001]
  • [Cites] Ann Intern Med. 1986 Feb;104(2):168-75 [3511812.001]
  • (PMID = 20146028.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


37. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica; 2009 Oct;94(10):1383-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
  • BACKGROUND: NOTCH1 mutations have been associated with a favorable outcome in pediatric acute T-lymphoblastic leukemia.
  • However, the results of studies on the prognostic significance of NOTCH1 mutations in adult T-lymphoblastic leukemia remain controversial.
  • DESIGN AND METHODS: Here we have investigated the prognostic impact of mutations in the NOTCH1 pathway, in particular, the NOTCH1 and FBXW7 genes, in a large cohort of adult patients with T-lymphoblastic leukemia (n=126).
  • In the overall cohort, no significant differences were seen in the complete remission or event-free survival rates between patients with mutated or wild-type NOTCH1-FBXW7 (p=0.39).
  • CONCLUSIONS: NOTCH1 and FBXW7 mutations were not predictive of outcome in the overall cohort of adult patients with T-lymphoblastic leukemia, but there was a trend towards a favorable prognostic impact of NOTCH1-FBXW7 mutations in the small subgroup of patients with low-risk ERG/BAALC expression status.
  • Our findings further confirm the high frequency of NOTCH1 mutations in adult T-lymphoblastic leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate / trends. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Sep 21;276(38):35847-53 [11461910.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1589-95 [12886247.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Semin Cell Dev Biol. 2005 Jun;16(3):323-33 [15840441.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:169-77 [17124057.001]
  • [Cites] Lancet. 2006 Nov 25;368(9550):1894-907 [17126723.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):2875-88 [17984302.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Leukemia. 2008 Jan;22(1):124-31 [17928886.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1154-60 [18368072.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Nat Med. 2009 Jan;15(1):50-8 [19098907.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [CommentIn] Haematologica. 2009 Oct;94(10):1338-40 [19794079.001]
  • (PMID = 19794083.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / Receptor, Notch1; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC2754954
  •  go-up   go-down


38. Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF, German AML Intergroup: Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica; 2008 Jun;93(6):826-33
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
  • BACKGROUND: The impact on quality of life of allogeneic stem cell transplantation or conventional chemotherapy in patients with acute myeloid leukemia remains unclear, mainly because of a lack of studies with long-term follow-up.
  • The patients' median age at diagnosis was 42 years, and the median follow-up period was 8 years.
  • One hundred and seventy patients were treated with stem cell transplantation (121 allogenic, 49 autologous) in first complete remission; the other 249 patients were treated with conventional chemotherapy.
  • RESULTS: The ECOG activity index revealed normal activity in 45% vs. 60% of the patients in the allogeneic stem cell transplantation vs. conventional chemotherapy groups, respectively and disabled person status in 60% vs. 35%.
  • All QLQ-C30 functions, except physical functioning and pain, were poorer in allogeneic stem cell transplantation patients.
  • Problems in leisure-time activities, social life, and financial management, sexual limitations and adverse effects were significantly more frequent in patients after allogeneic stem cell transplantation than after conventional chemotherapy.
  • Multivariate logistic regression models on global health status revealed concomitant disease, age > 45 years, and allogeneic stem cell transplantation as significant risk factors.
  • CONCLUSIONS: These results indicate that, compared to conventional chemotherapy, allogeneic stem cell transplantation has a significantly worse long-term impact on quality of life.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Remission Induction
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Health Status. Humans. Male. Middle Aged. Quality of Life. Time Factors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Jun;93(6):801-5 [18515876.001]
  • (PMID = 18469349.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


39. Fujisawa S, Tanioka F, Matsuoka T, Ozawa T, Naito K, Kobayashi M: CD7/CD19 double-positive T-cell acute lymphoblastic leukemia. Int J Hematol; 2006 May;83(4):324-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD7/CD19 double-positive T-cell acute lymphoblastic leukemia.
  • We report a rare case of T-cell acute lymphoblastic leukemia (T-ALL) with an aberrant phenotype.
  • Neither T-cell receptor gamma nor immunoglobulin heavy chain rearrangement was detected in the neck LN.
  • The response was so effective that complete remission (CR) was easily attained.
  • The patient is now under maintenance therapy in the first CR without hematopoietic cell transplantation.
  • [MeSH-major] Antigens, CD19. Antigens, CD7. Head and Neck Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Disease-Free Survival. Humans. Male. Middle Aged. Radiography. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Dec;12(12):2038 [9844938.001]
  • [Cites] Am J Hematol. 2004 Oct;77(2):156-60 [15389907.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):132-7 [15894924.001]
  • [Cites] Br J Haematol. 1998 Feb;100(2):291-4 [9488615.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):64-6 [9107085.001]
  • [Cites] J Clin Invest. 1984 Aug;74(2):332-40 [6378973.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):1-11 [12499424.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Semin Nucl Med. 1976 Oct;6(4):397-409 [185721.001]
  • [Cites] Int J Hematol. 1997 Dec;66(4):479-91 [9479874.001]
  • [Cites] Blood. 1983 Nov;62(5):1108-13 [6354305.001]
  • (PMID = 16757432.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD7
  •  go-up   go-down


40. Rojas JM, Wang L, Owen S, Knight K, Watmough SJ, Clark RE: Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol; 2010 Dec;38(12):1209-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
  • OBJECTIVE: Clinical presentation of chronic myeloid leukemia (CML) requires not only the deregulated tyrosine kinase BCR-ABL, but also the failure of an immune response against BCR-ABL-expressing cells.
  • T-cell responses against BCR-ABL and other antigens are well-described, but their relevance to the in vivo control of CML is unclear.
  • The suppressive role of naturally occurring T regulatory (T-reg) cells in antitumor immunity is well-established, although little is known about their role in modulating the T-cell response to BCR-ABL.
  • Their function was studied by observing their effect on responses to purified protein derivative, a recall antigen, and on the response of an autologous T-cell line recognizing BCR-ABL.
  • T-reg numbers in patients in complete cytogenetic remission were significantly lower than in patients not in complete cytogenetic remission (p < 0.01).
  • T-reg cell depletion using anti-CD25 selection enhanced proliferative responses to purified protein derivative.
  • [MeSH-major] Forkhead Transcription Factors / analysis. Immune Tolerance. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adult. Aged. Female. Fusion Proteins, bcr-abl / genetics. Humans. Immunologic Memory. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20854875.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


41. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol; 2010 Sep 20;28(27):4177-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
  • PURPOSE: Human T-cell lymphotropic virus type-I-associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy.
  • In acute ATL, achievement of complete remission with antiviral therapy resulted in 82% 5-year survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antiviral Agents / administration & dosage. Chi-Square Distribution. Female. Great Britain. Humans. Interferon-alpha / administration & dosage. Kaplan-Meier Estimate. Male. Martinique. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. United States. Young Adult. Zidovudine / administration & dosage

  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Dec 20;28(36):e765; author reply e766 [20921454.001]
  • (PMID = 20585095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


42. Takizawa J, Aoki S, Kurasaki T, Higashimura M, Honma K, Kitajima T, Momoi A, Takahashi H, Nakamura N, Furukawa T, Aizawa Y: Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol; 2007 Dec;82(12):1113-5
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation.
  • This study reports the first well-documented case of adult T-cell leukemia (ATL) successfully treated with unrelated cord blood transplantation (UCBT).
  • Chemotherapy induced complete remission, but the human T-cell leukemia virus type 1 (HTLV-1) proviral load was detected in mononuclear cells of her peripheral blood.
  • She remains in remission 30 months after UCBT and the HTLV-1 proviral load has fallen to undetectable levels.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696205.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


43. Bernasconi P, Calatroni S, Giardini I, Inzoli A, Castagnola C, Cavigliano PM, Rocca B, Boni M, Quarna J, Zappatore R, Caresana M, Bianchessi C, Pallavicini EB, Lazzarino M: ABL1 amplification in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2005 Oct 15;162(2):146-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABL1 amplification in T-cell acute lymphoblastic leukemia.
  • ABL1 amplification, due to a cryptic episomal translocation NUP214/ABL1, is a novel finding in T-cell acute lymphoblastic leukemia (ALL).
  • Here we report on the incidence and clinical features of this genetic defect in a series of 30 consecutive adult T-cell ALL patients.
  • Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) demonstrated that in these patients ABL1 gene expression was 14- and 18-fold greater than in normal controls, and returned to normal levels only when complete remission was achieved.
  • (1) FISH is the only technique that promptly identifies T-cell ALL patients with ABL1 amplification, (2) quick identification with FISH is fundamental in the clinic because this T-cell ALL subset is imatinib sensitive but may become resistant due to development of additional mutations, and (3) ABL1 quantitative RT-PCR may be easily applied to monitor minimal residual disease.
  • [MeSH-major] Genes, abl. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Aged. Child. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213363.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • According to recent gene expression profiling data, T-ALL and T-LBL can be separated by prediction analysis of microarrays showing an overexpression of MML1 in T-LBL and CD47 in T-ALL.
  • Immunophenotypes of T-LBL and T-ALL are identical but differ in frequency, with a higher rate of cortical or mature immunophenotypes in T-LBL, which is probably related to the higher rate (> 90%) of mediastinal tumors.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • T-ALL remission rates are 90%, and overall survival (OS) has improved to 60%-70%.
  • Mediastinal tumors resolve in most cases of T-ALL with chemotherapy only, whereas in T-LBL additional mediastinal irradiation seems to be beneficial.
  • Strategies for stem cell transplantation (SCT) in T-LBL and T-ALL differ.
  • Autologous SCT in complete remission (CR) in T-LBL gives a 70% survival rate, which is similar to chemotherapy alone.
  • In T-ALL, the subtypes of early and mature T-ALL have a poor outcome with chemotherapy alone (< 30%) and might profit from an allogeneic transplantation in first CR (OS > 50%).
  • MRD may guide further treatment strategies in T-ALL and probably also in T-LBL as indications for a SCT or for the evaluation of novel, particularly T-cell-specific, drugs.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Mediastinum / pathology. Medical Oncology / methods. Middle Aged. Prognosis. Remission Induction. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


45. Takeuchi K, Hattori T, Masuda S, Usui S, Oka K, Sakaida H, Majima Y: Cochlear implantation in complete remission in a patient with leukemia. Acta Otolaryngol; 2008 Jul;128(7):821-3
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation in complete remission in a patient with leukemia.
  • Patients with leukemia have an increased risk of developing sensorineural hearing loss.
  • This is a retrospective review of a profoundly deafened patient with acute myelogenous leukemia who underwent cochlear implantation.
  • The 26-year-old patient was successfully implanted with a Nucleus cochlear implant in the complete remission after peripheral blood stem cell transplantation.
  • To our knowledge, this is the first reported case of successful cochlear implantation in a patient deafened by acute myelogenous leukemia.
  • [MeSH-major] Cochlear Implantation / methods. Hearing Loss, Sensorineural / surgery. Leukemia, Myeloid, Acute / complications
  • [MeSH-minor] Adult. Follow-Up Studies. Humans. Male. Peripheral Blood Stem Cell Transplantation / methods. Remission Induction / methods. Speech Perception / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568527.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


46. Yamada K, Mizusawa M, Harima A, Kajiwara K, Hamaki T, Hoshi K, Kozai Y, Kodo H: Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults. Eur J Haematol; 2006 Oct;77(4):345-8
Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults.
  • Low-dose cytarabine and calcitriol (LDCA + VD3) combination therapy was performed in two adult patients with acute myeloid leukemia (AML) that relapsed within 1 yr after unrelated donor cord blood transplantation (URD CBT) performed in a relapse or non-remission stage.
  • Remission because of recovery of donor cord blood hematopoiesis was obtained in both patients.
  • The patients were followed as outpatients after remission, and the remission duration was approximately 6 months in both patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid / surgery. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930144.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 74KXF8I502 / Aclarubicin; FXC9231JVH / Calcitriol
  •  go-up   go-down


47. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).
  • These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


48. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, Otterud B, Maas F, Woestenenk R, Kester M, Leppert M, Schattenberg AV, de Witte T, van de Wiel-van Kemenade E, Dolstra H: A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest; 2005 Dec;115(12):3506-16
Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
  • Minor histocompatibility antigens (mHAgs) constitute the targets of the graft-versus-leukemia response after HLA-identical allogeneic stem cell transplantation.
  • Here, we have used genetic linkage analysis to identify a novel mHAg, designated lymphoid-restricted histocompatibility antigen-1 (LRH-1), which is encoded by the P2X5 gene and elicited an allogeneic CTL response in a patient with chronic myeloid leukemia after donor lymphocyte infusion.
  • Tetramer analysis showed that emergence of LRH-1-specific CD8+ cytotoxic T cells in peripheral blood and bone marrow correlated with complete remission of chronic myeloid leukemia.
  • Furthermore, the restricted expression of LRH-1 in hematopoietic cells including leukemic CD34+ progenitor cells provides evidence of a role for LRH-1-specific CD8+ cytotoxic T cells in selective graft-versus-leukemia reactivity in the absence of severe graft-versus-host disease.
  • These findings illustrate that the P2X5-encoded mHAg LRH-1 could be an attractive target for specific immunotherapy to treat hematological malignancies recurring after allogeneic stem cell transplantation.
  • [MeSH-major] Frameshift Mutation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Polymorphism, Genetic. Receptors, Purinergic P2 / genetics. Receptors, Purinergic P2 / metabolism. T-Lymphocytes, Cytotoxic / cytology
  • [MeSH-minor] Adult. Amino Acid Sequence. Antigens, CD34 / biosynthesis. Antigens, CD45 / chemistry. Base Sequence. Bone Marrow Cells / cytology. CD8-Positive T-Lymphocytes / metabolism. Cell Line. Cells, Cultured. Chromium / metabolism. Chromosome Mapping. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Epitopes / chemistry. Female. Fusion Proteins, bcr-abl / chemistry. Genetic Linkage. Genetic Markers. Genotype. Graft vs Leukemia Effect. HLA-B Antigens / chemistry. HLA-B7 Antigen. Haplotypes. Homozygote. Humans. Interferon-gamma / metabolism. Lod Score. Male. Models, Genetic. Molecular Sequence Data. Neurons / metabolism. Pedigree. Peptides / chemistry. Plasmids / metabolism. Receptors, Purinergic P2X5. Recurrence. Retroviridae / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stem Cell Transplantation. Stem Cells. T-Lymphocytes / cytology. T-Lymphocytes / immunology. Time Factors. Transcription Factors / genetics. Transplantation, Homologous

  • Genetic Alliance. consumer health - Chronic Myeloid Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2003 May 19;197(10):1279-89 [12743171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Blood. 2003 Jul 15;102(2):621-9 [12663445.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2885-91 [12842998.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2677-82 [14630824.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):371-80 [15122208.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):685-702, x [15271400.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Nature. 1990 Jan 18;343(6255):275-8 [1689009.001]
  • [Cites] Genomics. 1990 Mar;6(3):575-7 [2184120.001]
  • [Cites] J Immunol. 1994 Jan 1;152(1):163-75 [8254189.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2049-54 [8091227.001]
  • [Cites] Science. 1995 Jun 9;268(5216):1476-80 [7539551.001]
  • [Cites] Science. 1995 Sep 15;269(5230):1588-90 [7667640.001]
  • [Cites] J Neurosci. 1996 Apr 15;16(8):2495-507 [8786426.001]
  • [Cites] Trends Neurosci. 1996 Aug;19(8):331-8 [8843602.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):560-5 [8992968.001]
  • [Cites] Immunity. 1997 Mar;6(3):273-81 [9075928.001]
  • [Cites] Bone Marrow Transplant. 1997 Jun;19(12):1205-12 [9208114.001]
  • [Cites] Immunol Rev. 1997 Jun;157:125-40 [9255626.001]
  • [Cites] Curr Opin Immunol. 1997 Oct;9(5):655-61 [9368774.001]
  • [Cites] FEBS Lett. 1997 Nov 24;418(1-2):195-9 [9414125.001]
  • [Cites] Science. 1998 Feb 13;279(5353):1054-7 [9461441.001]
  • [Cites] Am J Hum Genet. 1998 Sep;63(3):861-9 [9718341.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):768-74 [9722305.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):301-8 [9892612.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2336-41 [10090944.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8639-44 [10411928.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1489-500 [12771180.001]
  • [Cites] J Immunol. 1999 Dec 15;163(12):6360-4 [10586024.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6229-34 [11086057.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):195-206 [11148223.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):107-18 [11171941.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1304-51 [11181995.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3223-30 [11544309.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):935-9 [12060133.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):345-55 [12135987.001]
  • [Cites] Tissue Antigens. 2002 Apr;59(4):293-303 [12135428.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2748-58 [12355426.001]
  • [CommentIn] J Clin Invest. 2005 Dec;115(12):3397-400 [16322786.001]
  • (PMID = 16322791.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA-Binding Proteins; 0 / Epitopes; 0 / Genetic Markers; 0 / HLA-B Antigens; 0 / HLA-B*07:02 antigen; 0 / HLA-B7 Antigen; 0 / P2RX5 protein, human; 0 / Peptides; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X5; 0 / Transcription Factors; 0R0008Q3JB / Chromium; 82115-62-6 / Interferon-gamma; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.1.3.48 / Antigens, CD45
  • [Other-IDs] NLM/ PMC1297240
  •  go-up   go-down


49. Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K, Molldrem JJ: PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One; 2010 Jul 26;5(7):e11770
Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.
  • BACKGROUND: Interferon-alpha (IFN) induces complete cytogenetic remission (CCR) in 20-25% CML patients and in a small minority of patients; CCR persists after IFN is stopped.
  • CONCLUSION: These data support the hypothesis that IFN elicits CML-specific CM CTL that may contribute to continuous CCR after IFN withdrawal and suggest a role for T cell immune therapy with or without tyrosine kinase inhibitors as a strategy to prolong CR in CML.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1998 May 4;187(9):1395-402 [9565632.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2529-34 [9326217.001]
  • [Cites] Leukemia. 1998 Jul;12(7):1076-80 [9665193.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):976-83 [9727066.001]
  • [Cites] Hematol Cell Ther. 1998 Oct;40(5):237-9 [9844819.001]
  • [Cites] J Immunol. 1999 Jan 15;162(2):989-94 [9916724.001]
  • [Cites] J Immunol. 1999 Feb 15;162(4):2227-34 [9973498.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2675-81 [10363991.001]
  • [Cites] Int Immunol. 1999 Jul;11(7):1027-33 [10383934.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2473-9 [15572591.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1299-305 [16288282.001]
  • [Cites] Blood. 2006 Jan 1;107(1):205-12 [16144796.001]
  • [Cites] Blood. 2007 Jul 15;110(2):770-5 [17412886.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1144-5 [17917659.001]
  • [Cites] Int J Hematol. 2007 Oct;86(3):208-11 [17988984.001]
  • [Cites] Cytotherapy. 2008;10(6):633-41 [18836918.001]
  • [Cites] J Clin Oncol. 2010 Mar 10;28(8):1429-35 [20142590.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):587-99 [10583264.001]
  • [Cites] Blood. 2000 Jan 15;95(2):404-8 [10627442.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1018-23 [10973322.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):106-11 [11242051.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28570-7 [11353767.001]
  • [Cites] J Immunol. 2001 Nov 1;167(9):4838-43 [11673487.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3074-81 [11698293.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47338-47 [12354776.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1033-41 [12569603.001]
  • [Cites] J Clin Invest. 2003 Mar;111(5):639-47 [12618518.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] Cytokines Cell Mol Ther. 2002;7(4):143-9 [14660054.001]
  • [Cites] Blood. 2004 Jan 15;103(2):538-44 [14504105.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1332-9 [15190258.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1094-9 [15100154.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Agents Actions. 1978 Jan;8(1-2):3-10 [345782.001]
  • [Cites] Blood. 1983 Sep;62(3):689-92 [6192858.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):87-95 [3463363.001]
  • [Cites] Cell. 1989 Dec 22;59(6):959-68 [2598267.001]
  • [Cites] Nature. 1992 Nov 19;360(6401):264-5 [1436108.001]
  • [Cites] J Clin Invest. 1994 Oct;94(4):1383-9 [7929813.001]
  • [Cites] Ann Intern Med. 1995 Feb 15;122(4):254-61 [7825760.001]
  • [Cites] Br J Haematol. 1995 Feb;89(2):250-7 [7873374.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7 [8633023.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):485-92 [8760802.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2450-7 [8839835.001]
  • [Cites] Int Immunol. 1998 Mar;10(3):311-23 [9576619.001]
  • (PMID = 20668669.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / CA016672; United States / NCI NIH HHS / CA / CA049639; United States / NCI NIH HHS / CA / CA100632; United States / NCI NIH HHS / CA / P01 CA049639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A2 Antigen; 0 / Interferon-alpha; 0 / Peptides; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2909896
  •  go-up   go-down


50. Fujita H, Nakaya A, Kato J, Tachibana T, Takemura S, Hyo R, Kawano T, Tanaka M, Taguchi J, Maruta A, Fujimaki K, Kanamori H, Ishigatsubo Y: [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid]. Rinsho Ketsueki; 2005 Oct;46(10):1095-9
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid].
  • Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases.
  • Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide.
  • Stem cell transplantation (SCT) has been widely adopted in CR2, but optimal SCT (auto- or allo-SCT) remains controversial.
  • Complete molecular remission has been maintained in the remaining 2 patients.
  • Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440769.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin
  •  go-up   go-down


51. Subbiah V, Viny AD, Rosenblatt S, Pohlman B, Lichtin A, Maciejewski JP: Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol; 2008 Sep;36(9):1078-83
Genetic Alliance. consumer health - Splenomegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia.
  • OBJECTIVE: T-cell large granular lymphocyte leukemia (T-LGL) is a chronic clonal lymphoproliferation of cytotoxic T cells often complicated by cytopenia.
  • Median spleen weight was 1300 g, consistent with diagnosis of splenomegaly; T-cell receptor (TCR)-gamma rearrangement and typical T-LGL were detected by immunophenotype in all specimens.

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] G Chir. 1999 Nov-Dec;20(11-12):479-86 [10645065.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):932-8 [18452068.001]
  • [Cites] Ann Rheum Dis. 2000 Nov;59(11):920-3 [11053074.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] N Engl J Med. 2002 Mar 28;346(13):995-1008 [11919310.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):291-2 [12531218.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):852-7 [15492568.001]
  • [Cites] Blood. 1986 Apr;67(4):914-8 [3485459.001]
  • [Cites] Br J Haematol. 1987 Oct;67(2):135-40 [3479187.001]
  • [Cites] Adv Surg. 1989;22:105-39 [2645743.001]
  • [Cites] Rinsho Byori. 1991 May;39(5):557-61 [1712868.001]
  • [Cites] Leuk Lymphoma. 1993 Jul;10(4-5):245-64 [8220125.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1620-7 [8068951.001]
  • [Cites] Blood Rev. 1996 Sep;10(3):177-84 [8932830.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):52-60 [8996124.001]
  • [Cites] Leuk Lymphoma. 1996 Oct;23(3-4):405-8 [9031124.001]
  • [Cites] Surgery. 1997 Jul;122(1):20-5 [9225910.001]
  • [Cites] Leukemia. 1998 Feb;12(2):150-4 [9519776.001]
  • [Cites] Blood. 1998 May 1;91(9):3372-8 [9558395.001]
  • [Cites] Br J Haematol. 2005 Feb;128(4):490-2 [15686456.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):245-66 [16530306.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):570-8 [16795070.001]
  • [Cites] N Engl J Med. 2006 Oct 19;355(16):1643-5 [17050888.001]
  • [Cites] Hematology. 2006 Aug;11(4):245-56 [17178663.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):30-7 [17092307.001]
  • [Cites] Br J Haematol. 2007 Jan;136(2):237-48 [17156396.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):141-50 [17387299.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):850-9 [17509982.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • (PMID = 18550263.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K24 HL077522; United States / NCI NIH HHS / CA / R01 CA113972; United States / NCRR NIH HHS / RR / U54 RR019397; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS67936; NLM/ PMC3537502
  •  go-up   go-down


52. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V, Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group: A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood; 2008 Nov 1;112(9):3574-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.
  • Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative treatment to patients with high-risk acute leukemia lacking a human leukocyte antigen-matched donor.
  • We analyzed 173 adults with acute myeloid leukemia (AML) and 93 with acute lymphoblastic leukemia (ALL) who received a haplo-HSCT in Europe.
  • All grafts were T cell-depleted peripheral blood progenitor cells from a direct family or other related donor.
  • At transplantation, there were 25 patients with AML in CR1 (complete remission 1), 61 in more than or equal to CR2, and 87 in nonremission, and 24 with ALL in CR1, 37 in more than or equal to CR2, and 32 in nonremission.
  • Leukemia-free survival at 2 years was 48% plus or minus 10%, 21% plus or minus 5%, and 1% for patients with AML undergoing transplantation in CR1, more than or equal to CR2, and nonremission, and 13% plus or minus 7%, 30% plus or minus 8%, and 7% plus or minus 5% in ALL patients, respectively.
  • In conclusion, haplo-HSCT can be an alternative option for the treatment of high-risk acute leukemia patients in remission, lacking a human leukocyte antigen-matched donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Europe / epidemiology. Female. Graft Survival. Graft vs Host Disease / etiology. Haplotypes / immunology. Humans. Lymphocyte Transfusion. Male. Middle Aged. Morpholines. Registries. Risk Factors. Tissue Donors. Treatment Outcome


53. de Labarthe A, Pautas C, Thomas X, de Botton S, Bordessoule D, Tilly H, de Revel T, Bastard C, Preudhomme C, Michallet M, Fenaux P, Bastie JN, Socié G, Cordonnier C, Dombret H, Acute Leukemia French Association: Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. Bone Marrow Transplant; 2005 Apr;35(8):767-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.
  • Through two consecutive trials, a policy that considered allogeneic stem cell transplantation (SCT) from a sibling donor in second rather than first complete remission (CR) in selected younger patients with acute myeloid leukemia (AML) with t(8;21)/inv(16) (core binding factor (CBF) group) or a normal karyotype (NN group) was followed by Acute Leukemia French Association (ALFA) centers.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adult. Gene Duplication. Humans. Karyotyping. Middle Aged. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Recurrence. Remission Induction. Retrospective Studies. Risk. Siblings. Time Factors. Tissue Donors. Translocation, Genetic. Treatment Outcome. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735660.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


54. Iwata Y, Wada T, Uchiyama A, Miwa A, Nakaya I, Tohyama T, Yamada Y, Kurokawa T, Yoshida T, Ohta S, Yokoyama H, Iida H: Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia. Intern Med; 2006;45(22):1291-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia.
  • We report a case with immunoglobulin A (IgA) nephropathy, showing IgA deposition which disappeared after peripheral blood stem cell transplantation (PBSCT) for acute lymphocytic leukemia (ALL).
  • After complete remission, urinary protein and hematuria remained at between (-) and (+/-).
  • [MeSH-major] Glomerulonephritis, IGA / complications. Glomerulonephritis, IGA / pathology. Immunosuppression. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Humans. Kidney / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170503.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Pérez-García A, Brunet S, Berlanga JJ, Tormo M, Nomdedeu J, Guardia R, Ribera JM, Heras I, Llorente A, Hoyos M, Esteve J, Besalduch J, Bueno J, Sierra J, Gallardo D, Grupo cooperativo para el estudio y tratamiento de las leucemias agudas: CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia; 2009 Mar;23(3):486-91
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
  • The recently described single-nucleotide polymorphism CT60, located in the 3'-untranslated region of the CTLA4 (cytotoxic T-lymphocyte antigen 4 ) gene, has been associated with susceptibility to several autoimmune diseases and has also been shown to be involved in immune responses following allogeneic stem cell transplantation (SCT).
  • However, the contribution of the CTLA4 genotype to the control of minimal residual disease in patients with acute myeloid leukemia (AML) has yet to be explored.
  • We investigated the association between the CTLA4 CT60 A/G genotype and the incidence of leukemic relapse in 143 adult patients with AML in first complete remission after the same chemotherapy protocol (CETLAM LAM'03).
  • [MeSH-major] Antigens, CD / genetics. Leukemia, Myeloid / drug therapy. Neoplasm Proteins / genetics
  • [MeSH-minor] 3' Untranslated Regions / genetics. Acute Disease. Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CTLA-4 Antigen. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Genotype. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Mitoxantrone / administration & dosage. Polymorphism, Single Nucleotide. Proportional Hazards Models. Recurrence. Remission Induction. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092854.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Antigens, CD; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Neoplasm Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  • [Investigator] Gallardo D; Guardia R; Fernández C; Brunet S; Nomdédeu JF; Hoyos M; Aventín A; Sierra J; Esteve J; Camós M; Rozman M; Villamor N; Costa D; Ribera JM; Granada I; Oriol A; Berlanga J; Duarte R; Alonso E; Bueno J; Sánchez E; Vallespí T; Pedro C; Florensa L; Soler F; Vivancos P; Torres P; De Llano MP; Tormo M; Besalduch J; Barnués M; Bargay J; Llorente A; Escoda L; García-Guiñón A; Font L; Martí-Tutusaus JM; Estany C; Pérez-García A; Gallardo D
  •  go-up   go-down


56. Arima N, Sugiyama T: [Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis]. Rinsho Ketsueki; 2005 Nov;46(11):1191-5
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis].
  • We present a patient with chronic adult T-cell leukemia, whose white blood cell count exceeded 100 X 10(9)/l, and end-stage renal disease, receiving long-term thrice-weekly dialysis.
  • Tumor lysis syndrome occurred 4 days after the course of the highest dose (3mg/m2), and the patient achieved complete remission.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Kidney Failure, Chronic / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pentostatin / administration & dosage. Renal Dialysis
  • [MeSH-minor] Chronic Disease. Dose-Response Relationship, Drug. Feasibility Studies. Female. Humans. Middle Aged. Models, Biological. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440802.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 395575MZO7 / Pentostatin
  •  go-up   go-down


57. Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK, Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D: Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. Acta Haematol; 2008;119(2):111-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality.
  • A 35-year-old female patient was diagnosed with acute myeloid leukemia with multiple genetic aberrations [48 XX, del(3)(q21), +6, t(11;15)(q23;q15), +21] including an 11q23/MLL abnormality.
  • The patient achieved a complete remission after one induction chemotherapy cycle.
  • After three courses of consolidation, a matched unrelated hematopoietic cell transplantation (HCT) was performed.
  • A bone marrow aspirate revealed 55% leukemic blasts carrying the unfavorable genetic aberrations seen at initial diagnosis (11q23/MLL).
  • In the absence of any disease-specific treatment, the leukemic blasts cleared from the bone marrow within 6 days after diagnosis of relapse and peripheral blood counts returned to normal.
  • This is the first report of spontaneous remission in a patient with initially a multiaberrant leukemic cell clone and a proven 11q23/MLL abnormality at relapse after HCT.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 11. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / pathology. Myeloid-Lymphoid Leukemia Protein / genetics
  • [MeSH-minor] Adult. Bone Marrow Examination. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence. Recurrence. Remission, Spontaneous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18367831.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


58. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI: Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica; 2009 Oct;94(10):1399-406
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.
  • BACKGROUND: Approximately 40% of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia achieve long-term survival following unrelated donor hematopoietic stem cell transplantation in first complete remission but severe graft-versus-host disease remains a problem affecting survival.
  • Although T-cell depletion abrogates graft-versus-host disease, the impact on disease-free survival in acute lymphoblastic leukemia is not known.
  • DESIGN AND METHODS: We analyzed the outcome of 48 adults (median age 26 years) with high-risk, Philadelphia-chromosome-negative acute lymphoblastic leukemia undergoing T-cell depleted unrelated donor-hematopoietic stem cell transplantation (67% 10 of 10 loci matched) in first complete remission reported to the British Society of Blood and Marrow Transplantation Registry from 1993 to 2005.
  • RESULTS: T-cell depletion was carried out by in vivo alemtuzumab administration.
  • Additional, ex vivo T-cell depletion was performed in 21% of patients.
  • High-risk cytogenetics at diagnosis was associated with a lower 5-year overall survival (47% (95% CI 27-71) vs. 68% (95% CI 44-84), p=0.045).
  • CONCLUSIONS: T-cell depleted hematopoietic stem cell transplantation from unrelated donors can result in good overall survival and low non-relapse mortality for adults with high-risk acute lymphoblastic leukemia in first complete remission and merits prospective evaluation.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Humanized. Female. Follow-Up Studies. Humans. Living Donors. Male. Middle Aged. Registries. Remission Induction. Risk Factors. Survival Rate / trends. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 2000 Feb;25(4):411-7 [10723585.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1245-52 [18940679.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(1):69-76 [10918407.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Cytotherapy. 2001;3(3):197-201 [12171726.001]
  • [Cites] Blood. 2003 Jul 1;102(1):404-6 [12623851.001]
  • [Cites] Ann Hematol. 2004 Apr;83(4):201-5 [14648023.001]
  • [Cites] Blood. 2004 May 15;103(10):3986-8 [14764530.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Lancet. 1987 Jul 25;2(8552):175-8 [2885638.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Transplantation. 1994 Oct 27;58(8):887-91 [7940731.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):305-8 [8704678.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):931-6 [9508175.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3308-13 [16046530.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Blood. 2008 Jul 15;112(2):426-34 [18398065.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3996-4003 [10845940.001]
  • (PMID = 19648167.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2754956
  •  go-up   go-down


59. Yanada M, Matsuo K, Emi N, Naoe T: Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer; 2005 Apr 15;103(8):1652-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.
  • BACKGROUND: The efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a human leukocyte antigen-identical sibling donor remains controversial for patients with acute myeloid leukemia (AML) in first complete disease remission (CR1).
  • Because the karyotype identified at diagnosis is the most relevant prognostic factor for AML, it should be possible to assess the efficacy more accurately on the basis of cytogenetic risk.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Cytogenetic Analysis. HLA Antigens / metabolism. Humans. Infant, Newborn. Middle Aged. Prognosis. Remission Induction. Survival Rate. Tissue Donors. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15742336.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Meta-Analysis; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


60. Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J, Soiffer RJ: Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol; 2008 Oct;83(10):771-7
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
  • The most important problem in the therapy of patients with acute myeloid leukemia (AML) is relapse after intensive therapy.
  • We sought to determine if interleukin-2 (low-dose with intermittent boluses) administration could be feasibly administered after standard therapy to potentiate anti-tumor immunity in a fashion analogous to the post-allogeneic stem cell transplant "graft-vs-leukemic" effect.
  • Patients achieving complete remission received high dose ara-C (HIDAC) for three courses followed by low dose rIL-2 (Amgen), administered by continuous infusion (450,000 U/m(2)/day) for 10 weeks with intermittent boluses (500,000/U/m(2) over 2 hr) given in weekly intervals starting on Week 4.
  • Mononuclear cells from patients receiving rIL-2 exhibited enhanced cytolytic activity in vitro against cryopreserved autologous leukemia cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Clinical Trials as Topic. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dose-Response Relationship, Drug. Fatigue / chemically induced. Feasibility Studies. Female. Fever / chemically induced. Follow-Up Studies. Humans. Interleukin-2 / administration & dosage. Interleukin-2 / genetics. Killer Cells, Natural / drug effects. Male. Middle Aged. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Remission Induction. Survival Analysis. T-Lymphocytes / drug effects. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18756547.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66996
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine
  •  go-up   go-down


61. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T: Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol; 2007 Mar;78(3):213-9
MedlinePlus Health Information. consumer health - Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.
  • BACKGROUND: Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).
  • METHODS: To investigate severe hemorrhagic complications during remission induction therapy with respect to incidence, risk factors, and influence on outcome.
  • Results were analyzed for 279 patients enrolled in the APL97 study conducted by the Japan Adult Leukemia Study Group (JALSG).
  • Nine of them succumbed to an early death, while the remaining nine patients eventually achieved complete remission (CR).
  • Risk factor analysis identified three pretreatment variables associated with severe hemorrhage: initial fibrinogen level, white blood cell count, and performance status.
  • [MeSH-major] Hemorrhage / etiology. Hemorrhage / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241371.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


62. Huang L, Lequin M, Pieters R, van den Heuvel-Eibrink MM: The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma. Pediatr Blood Cancer; 2007 Apr;48(4):468-72
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of follow-up examinations in childhood T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The aim of this study was to evaluate the value of follow-up investigations of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL), including cerebrospinal fluid (CSF) examination, bone marrow (BM) aspiration, peripheral blood (PB) count, serum lactate dehydrogenase (LDH) and chest X-rays in patients with an initial mediastinal enlargement.
  • T-ALL (13/30) with mediastinal enlargement at first diagnosis relapsed versus 2/16 of those without mediastinal enlargement.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / blood. Bone Marrow Examination. Child. Child, Preschool. Diagnostic Tests, Routine. Disease Management. Follow-Up Studies. Humans. Incidence. Infant. L-Lactate Dehydrogenase / blood. Leukemic Infiltration / diagnosis. Leukemic Infiltration / epidemiology. Mediastinum / pathology. Prognosis. Recurrence. Remission Induction. Retrospective Studies


63. Gorin NC, Labopin M, Frassoni F, Milpied N, Attal M, Blaise D, Meloni G, Iori AP, Michallet M, Willemze R, Deconninck E, Harousseau JL, Polge E, Rocha V: Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol; 2008 Jul 1;26(19):3183-8
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
  • PURPOSE: Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities.
  • They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses.
  • PATIENTS AND METHODS: From 1990 to 2004, 325 adult patients received transplantations in CR1 (159 patients with inv16 and 166 patients with t(8;21), including 35 and 60 patients, respectively, with additional chromosomal abnormalities).
  • RESULTS: In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively.
  • Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Chromosome Inversion. Chromosomes, Human, Pair 16. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Recurrence. Remission Induction. Retrospective Studies. Statistics, Nonparametric. Surveys and Questionnaires. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506024.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, Tomonaga M, Harada M, Kimura N, Masuda M, Kawano F, Yufu Y, Hattori H, Kikuchi H, Saburi Y: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood; 2005 May 15;105(10):4143-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma.
  • Sixteen patients with adult T-cell leukemia/lymphoma (ATL) who were all over 50 years of age underwent allogeneic stem cell transplantation with reduced-conditioning intensity (RIST) from HLA-matched sibling donors after a conditioning regimen consisting of fludarabine (180 mg/m2), busulfan (8 mg/kg), and rabbit antithymocyte globulin (5 mg/kg).
  • Three patients who had a relapse subsequently responded to a rapid discontinuation of the immunosuppressive agent and thereafter achieved another remission.
  • After RIST, the human T-cell leukemia virus type 1 (HTLV-1) proviral load became undetectable in 8 patients.
  • [MeSH-major] Immunotherapy. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation. Transplantation Conditioning

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665110.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


65. Yoshimoto G, Nagafuji K, Miyamoto T, Kinukawa N, Takase K, Eto T, Kato K, Hayashi S, Kamimura T, Ohno Y, Taniguchi S, Harada M: FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant; 2005 Dec;36(11):977-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
  • We retrospectively analysed the significance of FLT3 mutations in patients with acute myeloid leukemia (AML) having a normal karyotype, who were treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT).
  • In all, 34 patients with normal karyotype AML in first complete remission receiving high-dose chemotherapy and auto-PBSCT were analysed based on the presence or absence of FLT3/ITDs and FLT3/D835.
  • White blood cell count (P=0.0087), serum concentration of lactate dehydrogenase (P=0.005), and percentages of peripheral blood (P=0.0131) and bone marrow (BM) blasts (P=0.0312) were significantly higher in patients showing the FLT3 mutations.
  • [MeSH-major] Leukemia, Myeloid / genetics. Leukemia, Myeloid / therapy. Mutation. Peripheral Blood Stem Cell Transplantation / methods. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Mutational Analysis. Female. Humans. Karyotyping. Male. Middle Aged. Mutation, Missense. Prognosis. Remission Induction. Retrospective Studies. Survival Analysis. Tandem Repeat Sequences. Transplantation, Autologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184177.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


66. Shimizu S, Yasui C, Koizumi K, Ikeda H, Tsuchiya K: Cutaneous-type adult T-cell leukemia/lymphoma presenting as a solitary large skin nodule: a review of the literature. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S115-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous-type adult T-cell leukemia/lymphoma presenting as a solitary large skin nodule: a review of the literature.
  • Adult T-cell leukemia/lymphoma (ATLL) often involves the skin.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Remission Induction. X-Ray Therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938020.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


67. Miyamura F, Kako S, Yamagami H, Sato K, Sato M, Terasako K, Kimura S, Nakasone H, Aoki S, Okuda S, Yamazaki R, Oshima K, Yoshinaga K, Higuchi T, Nishida J, Demitsu T, Kakehashi A, Kanda Y: Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol; 2009 Oct;90(3):397-401
MedlinePlus Health Information. consumer health - Eczema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation.
  • Only some carriers of human T cell lymphotropic virus type I (HTLV-1) develop adult T cell leukemia/lymphoma (ATLL) after a long latency period, and an association has been reported between chronic refractory eczema, known as infective dermatitis, and young-onset ATLL.
  • A 25-year-old female developed ATLL and underwent allogeneic hematopoietic stem cell transplantation (HSCT) in non-remission.
  • Remission of ATLL was achieved, and the HTLV-1 proviral load decreased after HSCT.
  • [MeSH-major] Corneal Diseases / therapy. Eczema / therapy. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Chronic Disease. Female. HTLV-I Infections / complications. Human T-lymphotropic virus 1. Humans. Transplantation, Homologous. Treatment Outcome. Viral Load


68. Grigg AP, Gibson J, Bardy PG, Reynolds J, Shuttleworth P, Koelmeyer RL, Szer J, Roberts AW, To LB, Kennedy G, Bradstock KF: A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning. Biol Blood Marrow Transplant; 2007 May;13(5):560-7
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
  • The role of allogeneic transplantation in patients with de novo acute myeloid leukemia in first complete remission (AML-CR1) is controversial.
  • Aiming to preserve a graft-versus-leukemia effect, but minimize morbidity and mortality from conditioning-related toxicity and graft-versus-host disease (GVHD), we conducted a prospective multicenter study of reduced-intensity conditioning (RIC) as preparation for peripheral blood stem cell sibling allografts in patients with intermediate or poor risk AML-CR1.
  • Donor T cell chimerism was rapid and generally complete, but complete myeloid chimerism was delayed.
  • [MeSH-major] Acute Disease / therapy. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Peripheral Blood Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Chimerism. Cyclophosphamide / therapeutic use. Disease-Free Survival. Female. Fertility. Graft vs Host Disease. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Prospective Studies. Transplantation, Homologous / methods. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448915.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


69. Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V, Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation: Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. Blood; 2010 Oct 28;116(17):3157-62
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.
  • The stem cell source for autologous transplantation has shifted from bone marrow to peripheral blood (PB).
  • We previously showed that relapse incidence in patients with acute myelocytic leukemia autografted in first remission (CR1) was greater with PB than bone marrow, and a poorer outcome was associated with a shorter CR1 to PB transplantation interval (≤ 80 days).
  • Leukemic and normal progenitors are CD34(+) and can be concomitantly mobilized; we assessed whether an association exists between the infused CD34(+) cell dose and outcome.
  • The infused CD34(+) cell doses were available for 772 patients autografted more than 80 days after CR1 and were categorized by percentiles.
  • By multivariate analysis, relapse was more probable in patients who received the highest dose (hazard ratio = 1.48; 95% confidence interval, 1.12-1.95; P = .005), and leukemia-free survival was worse (hazard ratio = 0.72; 95% confidence interval, 0.55-0.93; P = .01).
  • In conclusion, in patients autografted in first remission, relapse was higher and leukemia-free survival lower for those who received the highest CD34(+) PB doses.
  • [MeSH-major] Antigens, CD34 / adverse effects. Leukapheresis. Leukemia, Myeloid, Acute / prevention & control. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Humans. Middle Aged. Multivariate Analysis. Prognosis. Recurrence. Remission Induction. Transplantation, Autologous. Young Adult

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479285.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ G0802523
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  • [Investigator] Milpied N; Blaise D; Witz F; Schattenberg A; Foa R; Attal MR; Bernal T; Maertens J; Rio B; Torres Gomez A; Harousseau JL; Cahn JY; Deconinck E; Michallet M; Delmer A; Alessandrino EP; Caillot D; Gratecos N; Ifrah N; Lioure B; Bordessoule D; Pogliani EM; Buzyn A; Bunjes D; Bay JO; De Blasio A; Indrák K; Iacopino P; Janssen JJ; Arcese W; Drenou B; Falda M; Iriondo Atienza A; Guilhot F; Lamy T; Schaafsma MR; Milone G; Guyotat D; Bosi A; Feremans W; Berthou C; Rodeghiero F; Levis A; Fremiotti A; Willemze R; Rizzoli V; Colombat P; Dreyfus F; Marianska B; Ljungman P; Ferrant A; Petersen E; Jouet JP; Cortelazzo S; Scimè R; Aljurf M; Bello López JL; Unal A; Caballero D; Rotoli B; Schubert J; Cantore N; Gorin NC; Cornelissen JJ; Solano C; Martinelli G; Sánchez de Toledo Codina J; Wijermans PW; Masszi T; Lasa Isasti R; Gallamini A; Zander AR; Schots R; Musso M; Metzner B; Botelho Sousa A; Apperley J; Schanz U; Carreras E; Bron D; Remes K; Di Bartolomeo P; Sierra J; Vernant JP; Zoumbos NC; Moicean A; Zuffa E; Aglietta M; Saglio G; Gutierrez Martín M; Gordon-Smith E; Pérez Equiza E; Urban C; Mistrik M; Gurman G; Wandt H; Afanasyev B; Fernández MN; Edwards D; Malm C; Duarte Palomino RF; Zambelli A; Vivancos P; Leoni P; Diez-Martin JL; Wiktor-Jedrzejczak W
  •  go-up   go-down


70. Giebel S, Labopin M, Holowiecki J, Labar B, Komarnicki M, Koza V, Masszi T, Mistrik M, Lange A, Hellmann A, Vitek A, Pretnar J, Mayer J, Rzepecki P, Indrak K, Wiktor-Jedrzejczak W, Wojnar J, Krawczyk-Kulis M, Kyrcz-Krzemien S, Rocha V: Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years. Ann Hematol; 2009 Oct;88(10):1005-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
  • The goal of this study was to analyze results and to determine factors affecting outcome of HLA-matched hematopoetic stem cells transplantation (MRD-HSCT) for patients with acute leukemia transplanted in first complete remission in Eastern European countries.
  • Six hundred forty HSCT were performed between 1990 and 2006 for adults with acute myeloid (n = 459) and lymphoblastic (n = 181) leukemia.
  • Two-year leukemia-free survival (LFS), nonrelapse mortality (NRM), and relapse incidence were 58 +/- 2%, 19 +/- 2%, and 23 +/- 2%, respectively.
  • We conclude that results of MRD-HSCT for acute leukemia in Eastern Europe improved over time as a consequence of decreased NRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Europe, Eastern. HLA Antigens. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19301005.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


71. Suga M, Yamaguchi M, Ichimiya M, Yoshikawa Y, Hamamoto Y, Muto M: A rare case of the cutaneous form of adult T-cell leukaemia/lymphoma: assessment of remission by PCR for clonal T-cell receptor gamma gene rearrangements in an electron beam-irradiated cutaneous lesion. Clin Exp Dermatol; 2005 Jan;30(1):40-2
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of the cutaneous form of adult T-cell leukaemia/lymphoma: assessment of remission by PCR for clonal T-cell receptor gamma gene rearrangements in an electron beam-irradiated cutaneous lesion.
  • Adult T-cell leukaemia/lymphoma is a lymphoproliferative disorder aetiologically associated with human T-cell lymphotropic virus type I infection.
  • Here we report a rare case of 'cutaneous' adult T-cell leukaemia/lymphoma with neither atypical cells in the peripheral blood nor lymph node involvement.
  • To evaluate whether or not there were residual lymphoma cells in the skin, we performed PCR to detect clonal T cell receptor gamma gene rearrangements.
  • [MeSH-major] Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Cutaneous / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663501.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ: Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood; 2007 Jul 1;110(1):409-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.
  • We compared the treatment-related mortality, relapse rate, disease-free survival (DFS), and overall survival (OS) by cytogenetic risk group of 261 patients with acute myeloid leukemia in first complete remission (CR1) and 299 patients in CR2 in undergoing matched unrelated donor hematopoietic stem cell transplantation (HSCT).
  • The graft-versus-leukemia effect appeared effective, even in patients with unfavorable cytogenetics.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] Hum Immunol. 1990 Oct;29(2):79-91 [2249952.001]
  • [Cites] Blood. 1993 Jan 1;81(1):249-53 [8417795.001]
  • [Cites] Leukemia. 1994 Apr;8(4):642-7 [8152258.001]
  • [Cites] Blood. 1994 May 15;83(10):3077-84 [8180404.001]
  • [Cites] Leukemia. 1995 Sep;9(9):1491-8 [7658718.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):203-8 [7581137.001]
  • [Cites] Bone Marrow Transplant. 1996 Jun;17(6):993-1001 [8807105.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):36-40 [9359499.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2931-8 [9376573.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1213-6 [9674854.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 1999 Jul 15;94(2):455-64 [10397713.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Br J Haematol. 2006 Mar;132(6):755-69 [16487177.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1673-82 [16871280.001]
  • [Cites] Bone Marrow Transplant. 1999 Nov;24(9):995-1003 [10556959.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1231-7 [10770306.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(4):397-404 [10982286.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] N Engl J Med. 2001 Jun 14;344(24):1815-22 [11407342.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2332-8 [11588027.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(5):257-60 [12064362.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(8):435-43 [12234169.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1915-9 [12738676.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • (PMID = 17374741.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1896123
  •  go-up   go-down


73. Chandesris MO, Ghez D, Besson C, Suarez F, Delarue R, Rubio MT, Bazarbachi A, Varet B, Hermine O: Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid? BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
  • Despite improvements in therapeutic options, human T cell lymphotropic virus type 1 (HTLV-1)-related adult T cell leukaemia/lymphoma (ATLL) has a dismal prognosis.
  • The present report concerns the case of a multirelapsing ATLL that reached a complete remission following the treatment of a secondary acute promyelocytic leukaemia with cytarabine, anthracyclin, all-transretinoic acid and arsenic trioxide.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):719-20 [17488707.001]
  • [Cites] Antiviral Res. 2006 Jul;70(3):132-9 [16540180.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2849-55 [11023521.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4576-82 [12560223.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]
  • [Cites] J Infect Dis. 2003 Aug 1;188(3):424-7 [12870124.001]
  • [Cites] Haematologica. 2007 Jun;92(6):753-62 [17550847.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:871-7 [15846376.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1010-7 [15843825.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Blood. 1999 Jan 1;93(1):278-83 [9864171.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):347-55 [15621824.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • (PMID = 21829417.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3030139
  •  go-up   go-down


74. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R: Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood; 2006 Jan 15;107(2):473-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol.
  • Between 1996 and 2000, 90 newly diagnosed adult patients with T-acute lymphoblastic leukemia (T-ALL) were registered in the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acuta Limfoide (LAL) 0496 protocol.
  • Fifty-six percent of patients with pro-T + pre-T-ALL achieved complete remission (CR) compared with 91% for cortical + mature cases (P = .002).
  • An extensive biologic workup of adult T-ALL cases at presentation is recommended in order to design tailored therapeutic strategies aimed at improving CR rates.
  • [MeSH-major] Chromosome Aberrations. Leukemia-Lymphoma, Adult T-Cell. Oncogene Proteins, Fusion / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Adolescent. Adult. Cytogenetic Analysis. Drug Resistance, Multiple. Female. Humans. Immunophenotyping. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179376.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / P-Glycoprotein
  •  go-up   go-down


75. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi M, Hatoum H, Rahimi H, Maleki M, Rafatpanah H, Rezaee SA, Yazdi MT, Shirdel A, de Thé H, Hermine O, Farid R, Bazarbachi A: Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood; 2009 Jun 25;113(26):6528-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
  • Adult T-cell leukemia/lymphoma (ATL) is resistant to chemotherapy and carries a dismal prognosis particularly for the acute and lymphoma subtypes.
  • In ATL cell lines, arsenic trioxide shuts off constitutive NF-kappaB activation and potentiates interferon-alpha apoptotic effects through proteasomal degradation of Tax.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Arsenicals / administration & dosage. Arsenicals / adverse effects. Drug Eruptions / etiology. Drug Synergism. Drug-Induced Liver Injury / etiology. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Human T-lymphotropic virus 1 / isolation & purification. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Male. Middle Aged. Oxides / administration & dosage. Oxides / adverse effects. Proviruses / isolation & purification. Remission Induction. Viral Load. Zidovudine / administration & dosage. Zidovudine / adverse effects

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19411628.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Interferon-alpha; 0 / Oxides; 4B9XT59T7S / Zidovudine; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


76. Janic D, Dokmanovic L, Jovanovic N, Lazic J: T-cell acute lymphoblastic leukemia in a child with ataxia-telangiectasia: case report. J Pediatr Hematol Oncol; 2007 Oct;29(10):713-5
MedlinePlus Health Information. consumer health - Ataxia Telangiectasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in a child with ataxia-telangiectasia: case report.
  • We present a patient with acute lymphoblastic leukemia and ataxia-telangiectasia (A-T).
  • At the age of 4 she was diagnosed with T-cell acute lymphoblastic leukemia and treated according to Berlin-Frankfurt-Munster strategy.
  • At present, the patient is in first remission and 2.5 years since the beginning of the treatment.
  • [MeSH-major] Ataxia Telangiectasia / complications. Leukemia-Lymphoma, Adult T-Cell / etiology
  • [MeSH-minor] Child, Preschool. Female. Humans. Remission Induction


77. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant; 2008 Apr;14(4):458-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
  • From 1985 to 2004, 49 patients with advanced myelodysplastic syndromes (MDS) (> or =5% blasts) or acute myeloid leukemia (AML) transformed from MDS underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or busulfan (5 patients).
  • Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their MDS (10 failures).
  • These results indicate that patients with advanced MDS who achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT.
  • [MeSH-major] HLA Antigens / immunology. Lymphocyte Depletion. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / immunology. Transplantation, Isogeneic / methods
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Graft vs Host Disease / prevention & control. Humans. Middle Aged. Remission Induction. Retrospective Studies. Siblings. Transplantation Conditioning / methods. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342789.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NCI NIH HHS / CA / P30 CA008748; United States / NHLBI NIH HHS / HL / R01 HL088134
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Other-IDs] NLM/ NIHMS43830; NLM/ PMC4498391
  •  go-up   go-down


78. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T: Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood; 2010 Aug 26;116(8):1369-76
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative option for adult T-cell leukemia (ATL), an intractable mature T-cell neoplasm causally linked with human T-cell leukemia virus type I (HTLV-I).
  • Multivariable analysis revealed 4 recipient factors significantly associated with lower survival rates: older age (> 50 years), male sex, status other than complete remission, and use of unrelated cord blood compared with use of HLA-matched related grafts.
  • Treatment-related mortality rate was higher among patients given cord blood transplants; disease-associated mortality was higher among male recipients or those given transplants not in remission.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Disease Progression. Female. Follow-Up Studies. Graft Survival. Human T-lymphotropic virus 1 / metabolism. Human T-lymphotropic virus 1 / pathogenicity. Humans. Japan / epidemiology. Male. Middle Aged. Retrospective Studies. Survival Rate. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479287.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


79. Suzuki S, Uozumi K, Maeda M, Yamasuji Y, Hashimoto S, Komorizono Y, Owatari S, Tokunaga M, Haraguchi K, Arima N: Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection. Int J Hematol; 2006 Jun;83(5):429-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia in a liver transplant recipient that did not progress after onset of graft rejection.
  • A liver allograft recipient developed acute-type adult T-cell leukemia (ATL) during tacrolimus treatment, 2 years after undergoing transplantation for subacute fulminant hepatitis.
  • Both donor and recipient were asymptomatic carriers of human T-cell lymphotropic virus type I (HTLV-I), but the ATL cells originated from the recipient.
  • The patient achieved complete remission, but the transplanted liver was acutely and chronically rejected.
  • Liver biopsies showed CD4+ ATL cell infiltration at the onset of ATL but not at the terminal stage.
  • [MeSH-major] Hepatitis / complications. Leukemia-Lymphoma, Adult T-Cell / etiology. Liver Failure, Acute / complications. Liver Transplantation. Living Donors


80. Au WY, Lam CC, Chim CS, Pang AW, Kwong YL: Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res; 2005 Oct;29(10):1213-5
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
  • Two patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody).
  • Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently.
  • Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Leukemia, T-Cell / drug therapy. Red-Cell Aplasia, Pure / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antilymphocyte Serum / administration & dosage. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Dexamethasone / administration & dosage. Humans. Male. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Remission Induction. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111536.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; 7S5I7G3JQL / Dexamethasone; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


81. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Adult. Child. Heart Valve Diseases / etiology. Heart Valve Diseases / pathology. Humans. Male. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601842.001).
  • [ISSN] 1880-1293
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Alekshun TJ, Tao J, Sokol L: Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol; 2007 Jun;82(6):481-5
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for t-cell large granular lymphocyte leukemia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature.
  • The majority of patients with T-cell large granular lymphocyte (LGL) leukemia will have an indolent clinical course.
  • Herein, we report a case of an aggressive T-cell LGL leukemia in a previously healthy 42-year-old Caucasian male who presented with acute onset of B-symptoms, hepatosplenomegaly, lymphocytosis, moderate anemia, and thrombocytopenia.
  • Immunophenotypically, the malignant cells co-expressed CD3(+)CD8(+)CD56(+) markers and the T-cell receptor beta (TCR beta) gene demonstrated clonal rearrangement.
  • The patient was treated with an intensive chemotherapeutic regimen (hyper-CVAD) and he achieved a complete remission.
  • A systematic review of all available English literature revealed 12 well-described cases of aggressive T-cell LGL leukemia suggesting that this variant is a new and distinct entity in the spectrum of LGL disorders.
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Follow-Up Studies. Humans. Immunophenotyping. Karyotyping. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Large granular lymphocyte leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17205534.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


83. Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F: T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res; 2007 Jul;31(7):939-45
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
  • T-cell large granular lymphocytic (T-LGL) leukemia is characterized by cytopenia and clonal proliferation of large granular lymphocytes.
  • We identified 26 patients with T-LGL leukemia seen at our institution over a period of 8 years.
  • The majority of the patients were asymptomatic at diagnosis.
  • Nine patients were treated with cyclosporine; one achieved a complete remission, and four had a hematological response.
  • We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients.
  • [MeSH-major] Leukemia, Lymphoid / pathology. Leukemia, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Cyclosporine / therapeutic use. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Pentostatin / therapeutic use. Retrospective Studies. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045649.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


84. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol; 2010 Apr 10;28(11):1878-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
  • PURPOSE Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals.
  • Hematopoietic cell transplantation (HCT) is generally not offered because of concerns of excess morbidity and mortality.
  • To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome


85. Gorin NC, Labopin M, Boiron JM, Theorin N, Littlewood T, Slavin S, Greinix H, Cahn JY, Alessandrino EP, Rambaldi A, Nagler A, Polge E, Rocha V, Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation: Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol; 2006 Aug 20;24(24):3959-66
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.
  • PURPOSE: Nucleated cell dose is an important and modifiable factor in hematopoietic stem cell transplantation (HSCT), however its association with outcomes in the context of reduced intensity conditioning regimen (RIC) HSCT for adults with acute myelocytic leukemia (AML) is not known.
  • One hundred forty one patients received transplants in first remission (CR1), 47 received transplants in second remission (CR2), and 65 patients received transplants in a more advanced phase.
  • The median nucleated and CD34 cell dose infused were 9.1x 10(8)/kg and 5.8x 10(6)/kg, respectively.
  • RESULTS: Overall, 2-year leukemia-free survival (LFS) was 41% +/- 4% and it was 46% +/- 5% for patients receiving a higher cell dose (> 9.1x 10(8)/kg) and 37% +/- 5% for the remainders (P = .03).
  • Higher cell doses exclusively benefited patients who received transplantations in CR2 or beyond, with LFS of 47 +/- 8 versus 20 +/- 8, with no detectable effect for patients who received transplants in CR1.
  • In a multivariate analysis of the overall patient population, higher nucleated cell dose cells were associated with higher LFS (P = .04), higher incidence of chronic graft-versus-host disease (P = .01), and there was a trend towards a lower relapse incidence (P = .06).
  • Interestingly, CD34+ cell dose was not associated with any outcomes.
  • CONCLUSION: Nucleated cell dose is an important factor that can be modified to improve results of RIC for patients with AML transplanted later than in CR1.
  • [MeSH-major] Antigens, CD34. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / surgery. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Europe. Female. Graft vs Host Disease / etiology. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880451.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


86. Marks DI: Treating the "older" adult with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2010;2010:13-20
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating the "older" adult with acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) in adults is a rare disease.
  • This article describes the results of chemotherapy and blood and marrow transplantation for Philadelphia chromosome negative and positive adult ALL in the "older" adult patient, but also critically examines the major controversies and suggests how they might be resolved.
  • The role of allografting in adult ALL is comprehensively discussed.
  • Results of recent studies on T-cell ALL and reduced-intensity allografting are reviewed.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239765.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm
  •  go-up   go-down


87. Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M: A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant; 2008 Jul;14(7):817-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
  • Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis.
  • Recently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the outcome.
  • Therefore, a graft-versus-leukemia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. HTLV-I Infections / blood. HTLV-I Infections / therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Retrospective Studies. Transplantation, Homologous. Viral Load

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Blood Marrow Transplant. 2008 Sep;14(9):1079
  • (PMID = 18541202.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


88. Dearden C: The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol; 2006 Apr;33(2 Suppl 5):S44-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of alemtuzumab in the management of T-cell malignancies.
  • T-cell malignancies are rare, making up 10% to 15% of all lymphoid neoplasms in adults.
  • They include many different types of disorders such as T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, adult T-cell leukemia/lymphoma, cutaneous T-cell lymphoma, and peripheral T-cell lymphoma, which are themselves divided into multiple subcategories.
  • Most T-cell malignancies arise as a result of chromosomal abnormalities, including T-cell receptor rearrangement anomalies.
  • Viral infections are implicated in the development of adult T-cell leukemia/lymphoma and some cases of peripheral T-cell lymphoma have been linked to Epstein-Barr virus or human immunodeficiency virus infection.
  • With the possible exception of T-cell large granular lymphocytic leukemia, which often has an indolent course, T-cell malignancies have not responded well to conventional chemotherapeutic treatment.
  • The introduction of monoclonal antibodies for the treatment of cancer has changed the outlook for patients with T-cell malignancies.
  • Recent studies with single-agent alemtuzumab, an anti-CD52 monoclonal antibody, have shown improved response rates and survival in patients with T-cell prolymphocytic leukemia and cutaneous T-cell lymphoma.
  • Preliminary data also suggest that alemtuzumab may have activity in patients with heavily pretreated peripheral T-cell lymphoma who are refractory to conventional chemotherapy.
  • Preclinical studies with mice bearing human adult T-cell leukemia/lymphoma cells suggest that alemtuzumab may have a potential therapeutic role in this setting.
  • Treatment of T-cell hematologic malignancies with alemtuzumab appears promising.
  • Earlier treatment and combination with chemotherapeutic agents may improve treatment outcome for patients with these malignancies and allow for consolidation with stem cell transplant strategies in selected patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Neoadjuvant Therapy. Remission Induction. Stem Cell Transplantation. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720203.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Number-of-references] 103
  •  go-up   go-down


89. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, Kobayashi T, Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol; 2006 Jan 20;24(3):460-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
  • PURPOSE: A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL).
  • RESULTS: Remission induction therapy resulted in complete remission (CR) in 77 patients (96.2%), resistant disease in one patient, and early death in two patients, as well as polymerase chain reaction negativity of bone marrow in 71.3%.
  • Allogeneic hematopoietic stem-cell transplantation (HSCT) was performed for 49 patients, 39 of whom underwent transplantation during their first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fusion Proteins, bcr-abl / metabolism. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Benzamides. Feasibility Studies. Female. Humans. Imatinib Mesylate. Japan. Male. Middle Aged. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344315.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


90. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M, Miglino M, Clavio M, Risso M, Frassoni F, Bacigalupo A: Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant; 2007 Aug;40(4):349-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.
  • We assessed the outcome of 170 patients with AML in first complete remission, aged 1-47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n=80 and n=90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years.
  • Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined (cyclosporine+methotrexate) GVHD prophylaxis.
  • In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. Humans. Infant. Italy / epidemiology. Male. Neoplasm Recurrence, Local / therapy. Remission Induction / methods. Risk. Survival Analysis. Transplantation, Homologous


91. Mokrzycka M, Pawlik A, Kałdońska M, Millo B: Assessment of liver function in children with acute lymphoblastic leukemia in remission. Ann Acad Med Stetin; 2006;52(3):61-5; discussion 65
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver function in children with acute lymphoblastic leukemia in remission.
  • PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignant neoplasm in children.
  • MATERIAL AND METHODS: We enrolled 17 children and young adults with ALL in remission.
  • Mean remission time was 61 +/- 30 months.
  • [MeSH-major] Liver Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Diagnosis, Differential. Female. Half-Life. Hepatitis, Chronic / complications. Hepatitis, Chronic / diagnosis. Humans. Lidocaine / analogs & derivatives. Lidocaine / pharmacokinetics. Liver / metabolism. Male. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385349.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7728-40-7 / monoethylglycinexylidide; 98PI200987 / Lidocaine
  •  go-up   go-down


92. Kikuchi M, Tanaka J, Kondo T, Hashino S, Kasai M, Kurosawa M, Iwasaki H, Morioka M, Kawamura T, Masauzi N, Fukuhara T, Kakinoki Y, Kobayashi H, Noto S, Asaka M, Imamura M: Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol; 2010 Oct;92(3):481-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
  • Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse.
  • We studied the value of MRD and showed a correlation with relapse for 34 adult patients with ALL.
  • MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) with probes derived from fusion chimeric genes (BCR/ABL) (n = 12) or PCR-based detection of clonal immunoglobulin and T cell receptor gene rearrangements (n = 16), or both (n = 6).
  • The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in complete remission (CR) patients with MRD level ≥ 10⁻³ (n = 12) were significantly lower than those in CR patients with MRD level <10(-3) (n = 15) (OS rate 79.0%, RFS rate 79.4%) (log-rank test, P = 0.017 and 0.0007).
  • MRD analysis on day 100 is important for treatment decision in adult ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Prognosis. Recurrence. Remission Induction. Stem Cell Transplantation. Survival Analysis. Transplantation, Homologous. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2007 May;92(5):612-8 [17488684.001]
  • [Cites] Leukemia. 2010 Mar;24(3):521-35 [20033054.001]
  • [Cites] Br J Haematol. 2002 Mar;116(3):686-94 [11849234.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Acta Haematol. 2004;112(1-2):111-9 [15179011.001]
  • [Cites] Haematologica. 2005 Nov;90(11):1516-23 [16266899.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2115-20 [11264179.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2315-23 [11895762.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):100-6 [19100372.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):774-82 [15755280.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Oct;23(5):1083-98, vii [19825454.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):71-90 [11987917.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5251-6 [8652840.001]
  • [Cites] Leukemia. 2004 May;18(5):934-8 [15029212.001]
  • [Cites] Br J Haematol. 2010 Jan;148(1):80-9 [19863538.001]
  • [Cites] Acta Haematol. 2004;112(1-2):8-15 [15178999.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):227-37 [18492099.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2602-9 [9116308.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):181-7 [16247752.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4153-62 [19141862.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1047-54 [19157547.001]
  • (PMID = 20830615.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


93. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan G, Singhal S, Mehta J: The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients. Bone Marrow Transplant; 2008 Jul;42(2):105-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients.
  • Age 30 years, >4 weeks to attain remission, and karyotypes t(4;11) and t(9;22) were associated with adverse outcome.
  • Maintenance chemotherapy after autotransplantation reduces relapse and improves outcome in adult patients with ALL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Transplantation, Autologous


94. Advani AS, Jin T, Ramsingh G, Tiu R, Saber W, Theil K, Sobecks R, Sekeres M, Copelan E, Sungren S, Tripp B, Kalaycio M: Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Aug;49(8):1560-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.
  • Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival.
  • On univariate analysis, significant prognostic factors included: age at diagnosis (per 10-year increase), poor risk cytogenetics, time to white blood count recovery, and time from induction chemotherapy (IC) to post-remission therapy (PRT).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Cytogenetic Analysis. Humans. Middle Aged. Prognosis. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766970.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Arat N, Bakanay SM, Yildiz E, Tufekcioglu O, Golbasi Z: Complete regression of massive cardiac involvement associated with acute T cell leukemia following chemotheraphy. Eur J Echocardiogr; 2008 May;9(3):388-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete regression of massive cardiac involvement associated with acute T cell leukemia following chemotheraphy.
  • Adult T cell leukemia/lymphomas are aggressive disorders, which infiltrate not only the bone marrow but extensively the visceral organs as well.
  • The dramatic improvement in echocardiographic findings after chemotherapy gave a clue to investigate suspected patients with aggressive leukemia and lymphomas for exclusion of leukemic infiltration of myocardium.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, T-Cell / drug therapy. Leukemia, T-Cell / pathology. Leukemic Infiltration. Myocardium / pathology
  • [MeSH-minor] Acute Disease. Adult. Humans. Male. Remission Induction. Ventricular Dysfunction, Left / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320483.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Kohno A, Morishita Y, Iida H, Yanada M, Uchida T, Hamaguchi M, Sawa M, Sugiura I, Yamamoto K, Mizuta S, Sao H, Naoe T, Miyamura K, Nagoya Blood and Marrow Transplantation Group: Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol; 2008 Mar;87(2):210-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group.
  • Acute promyelocytic leukemia (APL) is the most curable subtype of acute myeloid leukemia.
  • Second complete remission (CR2) can be easily achieved with several therapeutic options even after relapse.
  • We retrospectively compared the outcome of autologous (auto) and allogeneic (allo) hematopoietic stem cell transplantation (HSCT) for patients with APL in CR2 or CR3.
  • Three autografted patients and one allografted patient relapsed, and one autografted patient and five allografted patients died without leukemia relapse.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Aug 1;90(3):1321-5 [9242568.001]
  • [Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]
  • [Cites] Blood. 2002 Feb 1;99(3):759-67 [11806975.001]
  • [Cites] Haematologica. 2004 May;89(5):621-2 [15136233.001]
  • [Cites] Ann Hematol. 1997 Nov-Dec;75(5-6):195-200 [9433375.001]
  • [Cites] Leukemia. 2000 Jun;14(6):1006-13 [10865965.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1073-90 [9694694.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2396-410 [15800332.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):137-58 [11987921.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):120-6 [15534358.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]
  • (PMID = 18301963.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


97. Babusikova O, Stevulova L, Fajtova M: Immunophenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma; 2009;56(6):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping parameters as prognostic factors in T-acute leukemia patients.
  • The main aim of this study represents the extension of our studies using multiparametric flow cytometry analysis for exact definition of membrane and intracellular (cytoplasmic and nuclear) markers of acute leukemia cells of T-phenotype.
  • The study of blasts of each patient with all available monoclonal antibodies targeted to T-cell differential antigens and against possible marker coexistence from different lineages has been performed.
  • The main aim was concerned to more proper T-ALL diagnosis and stage definition and identification of the prognostic factors and the useful markers for the follow-up of T-ALL in remission.
  • New knowledge of the T-cell maturation stages of hematopoietic cells in bone marrow and thymus has been applied, as each T-acute leukemia clone is representative of one blocked stage through maturation.
  • Patients with more favorable prognosis (i. e. those of cortical stage) could have been already differentiated at diagnosis from those, allocated to pro-T stage, with very immature phenotypes and of an unfavorable clinical course.
  • The patients were either completely unresponsive to therapy or because of persistent MRD during continuation therapy, indicated for allogeneic hematopoietic stem-cell transplant.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. Biomarkers, Tumor / immunology. HLA-DR Antigens / analysis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual / immunology. Phenotype. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728759.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens
  •  go-up   go-down


98. Schrauder A, Reiter A, Gadner H, Niethammer D, Klingebiel T, Kremens B, Peters C, Ebell W, Zimmermann M, Niggli F, Ludwig WD, Riehm H, Welte K, Schrappe M: Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol; 2006 Dec 20;24(36):5742-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.
  • PURPOSE: The role of hematopoietic stem-cell transplantation (SCT) in first complete remission (CR1) for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is still under critical discussion.
  • T-cell ALL (T-ALL) patients with poor in vivo response to initial treatment represented the largest homogeneous subgroup within VHR patients.
  • The median time to SCT was 5 months (range, 2.4 to 10.8 months) from diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


99. Gorin NC, Labopin M, Blaise D, Reiffers J, Meloni G, Michallet M, de Witte T, Attal M, Rio B, Witz F, Fouillard L, Willemze R, Rocha V, Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation: Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. J Clin Oncol; 2009 Aug 20;27(24):3987-93
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission.
  • PURPOSE: The cell source for autologous stem cell transplantation has shifted from bone marrow (BM) to peripheral blood (PB).
  • In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source.
  • This translated into a significantly worse leukemia-free survival (LFS) for early PB transplantation (36% +/- 3%; HR, 0.75; 95% CI, 0.58 to 0.96; P = .02) and a trend for a poorer LFS for late PB (46% +/- 2%; HR, 0.84; 95% CI, 0.7 to 1.01; P = .06) as compared with BM (52% +/- 2%).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Recurrence. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 20;28(15):e246-7; author reply e248-9 [20368550.001]
  • (PMID = 19597030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A: Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia; 2007 Jun;21(6):1183-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.
  • Here, we report on seven FIP1L1-PDGFRA-positive patients who presented with acute myeloid leukemia (AML, n=5) or lymphoblastic T-cell non-Hodgkin-lymphoma (n=2) in conjunction with AML or Eos-MPD.
  • Patients were treated with imatinib (100 mg, n=5; 400 mg, n=2) either as monotherapy (n=2), as maintenance treatment after intensive chemotherapy (n=3) or in overt relapse 43 and 72 months, respectively, after primary diagnosis and treatment of FIP1L1-PDGFRA-positive disease (n=2).
  • All patients are alive, disease-free and in complete hematologic and complete molecular remission after a median time of 20 months (range, 9-36) on imatinib.
  • The median time to achievement of complete molecular remission was 6 months (range, 1-14).
  • [MeSH-major] Eosinophilia / drug therapy. Leukemia, Myeloid / drug therapy. Oncogene Proteins, Fusion / analysis. Piperazines / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Receptor, Platelet-Derived Growth Factor alpha. mRNA Cleavage and Polyadenylation Factors
  • [MeSH-minor] Acute Disease. Adult. Aged. Benzamides. Disease-Free Survival. Humans. Imatinib Mesylate. Male. Middle Aged. Myeloproliferative Disorders / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Remission Induction / methods






Advertisement